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I. INTRODUCTION
On the eve of the landmark 1994 election, the Democraticallycontrolled Congress unanimously passed, and President Clinton signed,
the Dietary Supplement Health and Education Act (DSHEA).' That law
exempted claims about the effects of dietary supplements on the human
body' from the drug provisions of the Federal Food Drug and Cosmetic
Act (FFDCA).' DSHEA also exempted supplements from other

1. Pub. L. No. 103-417, 108 Stat. 4325 (1994) (codified as amended in various sections
of 21 U.S.C.). DSHEA became law on Oct. 25, 1994. Id. In the November election, the
Republican party became a majority in both houses of Congress. Adam Clymer, G.O.P
Celebrates Its Sweep to Power,Clinton Vows to Find Common Ground, N.Y. TIMES, Nov. 10,

1994, at Al.
2. 21 U.S.C. §§ 321(g)(1) & 343(r)(6)(A) (1994).
3. 21 U.S.C. §§ 301-397.
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provisions of the FFDCA and established new standards for claims and
safety determinations for supplements.
At the same time, DSHEA defined dietary supplements broadly to
include herbs and other dietary substances used to supplement the diet.'
Dietary supplements have long included vitamins and minerals. Over
time, products have been sold as supplements that did not have a
recognized nutritional value, and even some without a history of use in
foods, and with a use in traditional medicine.6 Under DSHEA, dietary
ingredients need not be nutrients, but the law has not provided guidance
on the broader new meaning of the term "dietary."7 The enactment of
DSHEA became a harbinger of a new era of re-examination of the
appropriate limits of regulatory power. Indeed, the term "being
DSHEAed" has become a byword for deregulation in some quarters.
This Article examines the changes made by DSHEA. While, under
DSHEA, the supplement manufacturers cannot make disease treatment
and prevention claims on the supplement labels, they now can make
"statements of nutritional support" claiming effects on the "structure or
function" of the body.' Before DSHEA, claims of this type for nonnutritional supplements would have been regarded as drug claims subject
to the pre-market approval and controlled testing ordinarily required for
drugs.9 This change creates ambiguity concerning the boundary between
drug claims and food claims. DSHEA also removes "publications" that
provide scientific information in connection with supplement sales from
the scope of the FDA's ability to regulate labeling claims (the "publication exemption"), opening up the possibility for disease treatment and

4. 21 U.S.C. § 321(s) (exemption from food additive definition); 21 U.S.C. § 343-2
(publication exemption); 21 U.S.C. § 343(r)(6) (statements of nutritional support); 21 U.S.C. §§
342(0, 350(b) (1994) (new safety provisions for supplements).
5. 21 U.S.C. § 321(ff) (1994).
6. See FDA Advance Notice of ProposedRulemaking, 21 C.F.R. ch. 1, Regulation of
Dietary Supplements, 58 Fed. Reg. 33,690, 33,697 (1993), reprintedin BASS & YOUNG, infra

note 56, at 307-19 (FDA notice reviewing' history of regulation of dietary supplements)
[hereinafter FDA Advance Notice].

The term "botanical" encompasses all plants, including herbs, which are "seed producing"
plants without "persistent woody tissue." WEBSTER'S THIRD NEW INTERNATIONAL DICTIONARY
258 (1963) (botanical); id. at 1058 (herb). This Article generally refers to "herbal remedies"
because of the greater familiarity of that term among consumers, but uses the term "botanical
products" when referring to the scientific recommendations of the Commission on Dietary
Supplement Labels. See infra text accompanying note 15.
7. 21 U.S.C. § 343(r)(6) (1994); infra pts. III.B. & C.
8. 21 U.S.C. § 343(r)(6)(A) (1994).
9. See Nutrilab, Inc. v. Schweiker, 713 F.2d 335 (7th Cir. 1983); discussion infra pt.
II.C.; 21 U.S.C. § 355 (1994); infra pts. W.A. & B. for a discussion of the new drug
requirements and the ways of satisfying the legal requirements governing drugs.
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prevention claims to be made for dietary supplements." As a result of
DSHEA, a vast range of new claims are being made regarding the
effects of supplements, including assertions that they help one think
better, improve the immune system, lower cholesterol, and are herbal
versions of prescription drugs."
DSHEA also revoked the authority of the Food and Drug Administration (FDA) to require pre-market approval of the safety of dietary
supplements, an authority that also had been narrowed by court
decisions. 2 The enactment of the safety provision of DSHEA has been
called Commissioner Kessler's "greatest failure" in his years as the head
of the FDA. 3 Kessler has commented that there are "certain problems
you are not going to solve" and dietary supplements are "one of
14
them."
This Article considers ways to implement DSHEA and methods that
may be used to provide additional protection to consumers even with the
reduced powers given to the FDA. It examines ways to distinguish
nutritional support statements from inappropriate claims by considering
factors to identify disease treatment and prevention claims, and the
"dietary" role of supplements. The Article discusses the type of testing
that manufacturers need to do to substantiate the claims made for
supplements. Manufacturers of supplements also should have an
enforceable obligation to substantiate the safety of all supplements, and
the FDA should be able to determine effectively whether manufacturers
have met their legal obligations of substantiating the safety of products
and any claims they make. In addition, this Article examines whether
the publication exemption should apply only to articles containing
scientific information that are written independently from manufacturers.
If the law can be interpreted as this Article suggests, the additional
safeguards will help provide minimal consumer protections while further
experience tests how well the DSHEA regulatory model works.
10. 21 U.S.C. § 343-2 (1994). The Federal Trade Commission (FTC) may regulate
misleading claims in publications that contain advertising, but its authority is different from the
FDA's and does not encompass pre-market approval of drug claims. See 15 U.S.C. §§ 45, 52

& 55 (1988).
11. See discussion infra pts. III.C.1. & C.2.b.
12. See 21 U.S.C. § 321(s)(6) (1994). For judicial decisions, see United States v. Oakmont
Inv. Co., 937 F.2d 33 (1st Cir. 1993); United States v. Vipone Ltd. Black Currant Oil, 984 F2d
814 (7th Cir. 1993); infra pt. III.E.2.
13. See Marian Burros, ED.A. Commissioner IsResigning After 6 Stormy Years inOffice,
N.Y. TIMES, Nov. 26, 1996, at Al ("Others see his inability to keep dangerous dietary
supplements off the market as his greatest failure. Under significant pressure from the dietary
supplement industry Congress passed legislation... to exempt from strict oversight supplements
like ephedra, which has caused several deaths.").
14. Id.at Al8.
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When Congress enacted DSHEA, it created an independent Commission on Dietary Supplements Labels (the Commission), to provide
recommendations on the use of health and other claims on dietary
supplements.15 I served as one of seven members appointed by the
President to the Commission, which issued its final report in November
1997.6 While this Article is an outgrowth of my work on the Commission, it reflects my views of the larger issues raised by that project. The
Article provides an analysis from a legal and academic perspective of
only some of the issues covered by the report. Moreover, on a number
of points, I stated views in the report that differed from other Commissioners or went beyond the recommendations of the Commission as a
whole. This Article reflects my personal views and is not a restatement
or summary of the work of the Commission.
Another major focus of this Article is the Commission's recommendation that a study be performed of an alternative system based on
international models for regulating therapeutic claims for herbal or
botanical supplements. In its report, most of the Commissioners
concluded that consumers would be better served by clear information
about the traditional therapeutic uses of botanicals when they have
scientific support, rather than by the use of DSHEA to suggest such uses
of
without overtly stating them, a process which may "create a climate
17 The
deception that serves neither the industry nor consumers."
Commission recommended a study of international models and "some
alternative system, for regulating the use of botanical remedies that do
not meet the requirements in this country for over-the-counter (OTC)
drugs."' 8 The Commission did not expressly recommend any lower
standard of approval for botanical remedies, but such a possibility is
inherent in a study of an alternative system for products that do not
meet the existing legal standards for drugs.
The recommendation for a study of an alternative system raises
difficult and important issues about whether there should ever be a
different standard for approval of disease treatment and prevention

15. 108 Stat. 4332 (codified at 21 U.S.C. § 343 note).
16. COMM'N ON DIETARY SUPPLEMENT LABELS, COMM'N ON DIETARY SUPPLEMENT

OF THE DEP'T OF HEALTH
LABELS REACr TO THE PRESIDENT, CONGRESS, AND THE SECRETARY

report,
AND HuMAN SERVICES (Nov. 1997) [hereinafter COMMISSION REPORT]. The Commission
017-001-00531-2
Office
Printing
Government
the
from
available
is
1997,
24,
issued November
and on the Internet at http://web.health.gov/dietsupp.
and focuses
This Article presents the perspective I gained from my work on the Commission
completed.
was
Commission
the
of
work
the
time
the
on the developments at
17. Id. at 56-57.
are
18. See id. at xi & 57. The issues concerning the scope of any alternative category
discussed infra pt. V.
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claims for some drugs and not others, as well as the safeguards that
would be needed. An alternative system can have different rationales.
Some may believe that efficacy can be adequately determined, based on
traditional use without controlled testing. The rationale that warrants
study, in my view, would not regard traditional use as an adequate basis
for determining efficacy, but would consider whether consumers should
have the freedom to use safe drugs not adequately proven to be effective
when these consumers are clearly and adequately informed about the
lack of testing. More investigation is needed concerning whether there
are adequate ways to protect consumers under such an approach.
Whether an alternative system for therapeutic claims on botanical
remedies would be better than the use of DSHEA to suggest such claims
presents a conundrum. Comparison is difficult because alternative
systems have yet to be studied and debated. Moreover, what is
permissible under DSHEA is itself ambiguous. Importantly, additional
guidance concerning the scope of permissible claims under DSHEA may
help eliminate some of the most questionable uses of nutritional support
statements to imply effectiveness for disease prevention and treatment.
Thus, regulatory action to address inappropriate claims under DSHEA
may indirectly reduce the need for an alternative system as a way of
protecting consumers from ambiguous claims.
If an alternative system is to be considered for botanical products,
thought also must be given to whether the alternative system should
encompass safe but unproven remedies for those suffering from lifethreatening and seriously debilitating illnesses such as cancer, AIDS,
blindness, and Alzheimer's disease. To prevent harm, use of these
products, even under a freedom-of-choice rationale, should still be
limited to use after consultation with a physician. The physician also
should be provided by the manufacturer with adequate information
concerning the deficiencies in the supporting evidence for the product
that the physician can use in advising the patient. Potent products and
supplements that pose risks of harm should continue to be governed by
the approval procedures governing new drugs.19
Finally, the existing legal system already indirectly provides a way
for consumers to exercise the freedom to use supplements for disease
prevention and treatment purposes by the very availability of products
sold simply as dietary supplements. Americans have an increasing

19. See, e.g., 21 U.S.C. § 355 (governing the introduction of new drugs into interstate
commerce); Pub. L. No. 105-115, §§ 112 & 402, 111 Stat. 2296, 2309-10, 2365-67 (enacting
§§ 506 and 551, to be codified as amended at 21 U.S.C. §§ 351 et seq.) (expediting the study
and approval of fast track drugs and regarding the dissemination of information on new drug
uses).
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interest in herbal remedies as well as in other alternatives to standard
health care.2' When products are sold as "dietary supplements," the
consumer is, and has long been able to use the supplements for
therapeutic uses not stated on the label.2 DSHEA safeguards the
availability of botanical and other dietary supplements even though
consumers may be using the products, on their own initiative, for drug
purposes. This means of giving consumers freedom-of-choice is
imperfect, but developing an alternative system of doing so also presents
difficulties. The political compromise represented by DSHEA is likely
to continue to have an important role in indirectly giving Americans the
choice to use supplements for disease purposes on an "off-label"
basis.'
Part II of this Article reviews the FDA's efforts to regulate dietary
supplements and its jurisdictional authority to regulate products as drugs.
That history provides perspective on the purpose, scope, and impact of
DSHEA. Part II also shows the difficulties the FDA has long had in
regulating dietary supplements as drugs based on consumer use in the
absence of claims attributable to the manufacturer.
Part Ill examines the new provisions of DSHEA that bear on the
ability of supplement manufacturers to make claims about the effects of
supplements on the body and analyzes tests for distinguishing dietary
supplement claims from inappropriate claims for disease prevention and
treatment or non-dietary effects claims. Part III also considers the scope
20. See, e.g., IsADORE ROSENFELD, DR. ROSENFELD'S GUIDE TO ALTERNATIVE MEDICINE
1 (1996) (noting that millions of Americans, especially the better educated, are spending
"billions" every year on "a wide variety of 'alternative, complementary,' or 'holistic' therapies
such as herbs, acupuncture, and meditation"); see generally Michael H. Cohen, A Fixed Star in
Health CareReform: The Emerging Paradigmof Holistic Healing, 27 ARIZ. ST. L.J. 79 (1995)
(examining the extent to which the legal system accommodates holistic healing methods); David
M. Eisenberg et al., Unconventional Medicine in the United States: Prevalence, Costs, and
Patternsof Use, 328 NEW ENG. J. MED. 246, 28 (Jan. 28, 1993) (reporting results of a survey
in which one-third of the American respondents reported using at least one unconventional
therapy in the previous year, and one-third of those saw unconventional therapy providers).
21. A notable example of consumer use of a dietary supplement for an off-label drug
purpose was reported by the New York Times personal health editor who used a supplement as
a remedy for an arthritic knee. See Jane E. Brody, PersonalHealth, N.Y. TIMES, Jan. 15, 1997,
at CIO ("I am only an anecdote of one, not a study that proves anything. Without a careful
scientific study, any personal account of benefit leaves open to question what actually caused
the improvement.").
See generally Scott Martin, Note, Unlabelled "Drugs"as U.S. Health Policy: The Casefor
Allowing Health Claims on Medicinal Herb Labels; Canada Provides a Model for Reform, 9
ARIz. J. INT'L & COMP. L. 545 (1992) (examining "the regulation of medicinal herbs in the
United States and Canada," and suggesting "that the FDA has the authority to regulate medicinal
herbs by a less restrictive 'effectiveness' standard than that used for conventional drugs").
22. See infra note 60 and accompanying text.
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of the publication exemption, the new provisions governing the safety
of supplements, and the need to ensure that the FDA has sufficient
authority to deal with safety and enforcement issues.
Some botanical products already may have the type of testing and
support necessary to be appropriately sold as OTC drugs under the
present law. Part IV of this Article considers the FDA's OTC review
program and the recommendations made by the Commission to
encourage the FDA to develop a process for evaluating botanical
remedies when the manufacturer has the studies and other support
needed for approval under the existing law.
Part V of this Article discusses the different rationales for an
alternative system of regulation for botanical remedies that would use
a less stringent standard. The advantages and drawbacks of these
rationales for an alternative system are examined in relationship to
DSHEA as a means of providing freedom of choice to consumers.
This Article specifically focuses on issues involving supplements that
consumers may use for therapeutic purposes. There are, however, many
dietary supplements that clearly are used by consumers only for
nutritional purposes. (One-a-day vitamin pills are the most obvious
example.) Discussion of such supplements is beyond the scope of this
Article.
II. THE FDA's

EFFORTS TO REGULATE DIETARY
SUPPLEMENTS AND THE JUDICIAL AND

CONGRESSIONAL RESPONSE: THE ROAD TO DSHEA

The history of the FDA's regulation of dietary supplements is
important in understanding the factors that led to the enactment of
DSHEA, and the role that supplements have increasingly played in
providing consumers with individual choices. A "bitter battle" has
occurred between the FDA and the dietary supplement industry about
when supplements can be considered to be drugs.23 In regulating
supplements, the FDA has tested the limits of its ability to regulate a
product as a drug based on various ways of determining the
manufacturer's intent. The agency has had some important victories over
legal principles, but legislative changes and court decisions have
substantially limited the FDA's authority to regulate supplements as
drugs based merely on consumer use without other evidence to show the
seller's intent to market the product as a drug.

23. The phrase is Judge Friendly's, who presided over some of the more contentious
chapters. National Nutritional Foods Ass'n v. Kennedy, 572 F.2d 377, 379 (2d Cir. 1978); see
also infra note 55.
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A. Early History of Court Enforcement and
Broad Interpretationof Labeling
Any ingested product, including a supplement, that is intended by its
manufacturer to prevent or treat a disease is a "drug" under the law.24
Products (other than foods) that are intended to affect the structure or
function of the body are also considered drugs.25 Misleading drug
claims originally were prohibited by the FFDCA as enacted in 1938.26
The drug efficacy amendment, enacted in 1962 in the wake of the
thalidomide tragedy, went further in requiring prior FDA approval of
drug effectiveness claims, based on adequate and well-controlled studies,
unless the product was generally recognized by experts as effective
based on similar studies.27
In the early years, vitamins, minerals, and herbs often were the
subject of FDA enforcement actions, which sometimes were based on
the FDA's authority to preclude misleading claims on foods. 2' The
FDA also would assert that the claims made for the product, in one way
or another, suggested a therapeutic purpose that did not meet the
applicable standards for drugs.29
The FDA had success in establishing a wide scope for its authority
to reach the indirect means used by manufacturers to make these drug
effectiveness claims. In a landmark case from the 1940s, involving
vitamins, the United States Supreme Court held that the "labeling"
covered by the Act included pamphlets mailed separately by the
manufacturer to retailers even when the material was not physically
attached to the product itself.3" The Court found that the pamphlets
performed the function of labeling by explaining the product's use, and
gave labeling a broad reading to ensure that the law not "be circumvent24. See 21 U.S.C. § 321(g)(1)(B) (defining "drug" in part as "articles intended for use in
the diagnosis, cure, mitigation, treatment, or prevention of disease").
25. 21 U.S.C. § 321(g)(1)(C); see discussion infra pt. III.C. (regarding the nonapplicability of this provision to statements of nutritional support for dietary supplements under
DSHEA).
26. See 21 U.S.C. § 352(a) (1994) (including legislative history).
27. See 21 U.S.C. § 355 (requiring filing and approval of an application prior to delivering

into interstate commerce any "new drug"); Weinberger v. Hynson, Westcott & Dunning, Inc.,
412 U.S. 609, 612-15 (1973) (discussing the historical development of the amendments
concerning drug efficacy); see infra pt. IV for further discussion of the efficacy provisions.
28. See 21 U.S.C. § 343(a)(1) (pertaining to false or misleading labels on food).
29. See V.E. Irons, Inc. v. United States, 244 E2d 34 (1st Cir. 1957); PETER B. HUTT &
RICHARD A. MERRILL, FOOD & DRUG LAW: CASES AND MATERIALS 207 n.2 (2d ed. 1991)

("The Irons case is illustrative of literally hundreds of court actions... against false or
misleading nutritional claims... under the food and drug sections of the Act.").
30. See Kordel v. United States, 335 U.S. 345, 349 (1948) (construing §§ 301(a), 502(0
& 201(m), in relationship to false labeling).
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ed."" Courts have recognized, however, that labeling does not include
books and written material by an independent author that may state
potential drug uses for a product, absent some showing of an integrated
plan to use the material to make claims for a product at the point of
sale, even though the writings are sold in the same store as the
product.32
The FDA and the Federal Trade Commission (FTC) brought
hundreds of court actions against misleading claims and advertisements
for nutrition products and "undoubtedly expended more enforcement
resources in the area of nutrition than in any other single field" through
the 1960s."3 This case-by-case enforcement approach, however, had
limited effectiveness, and ultimately the FDA looked to the use of
rulemaking as a means to regulate claims on supplements.
B. FDA Regulations and Response: Consumer
Use and Drug Intent
In rules issued in the 1940s, the FDA recognized the food value of
certain dietary supplements, but did not seek to preclude claims for
other supplements, and instead required a label disclaimer stating that
the need for the substance "in human nutrition has not been established. ' 34 The FDA later became dissatisfied with the disclosure,
because consumers might read it as suggesting that evidence of
nutritional value was imminent.35
In 1962, the FDA began a regulatory effort to withdraw the "crepe
labeling," and limit dietary supplements containing vitamins and
minerals to uses for which there was a recognized nutritional need.36
The FDA sought to refute the "myths of nutrition": that the modem
processing of foods "strips them" of virtually all nutritional value, that
it is "essentially impossible to obtain from our daily diets the nutrients
we require," and that nearly everyone may suffer "from a subclinical
nutritional deficiency."37
The difficulty was that many consumers and even some professionals
believed in the "myths," and also believed that "optimal" nutrition
31. See id. at 350.
32. See United States v. Sterling Vinegar & Honey, 338 F2d 157, 158 (2d Cir. 1964).
33. HUTT & MERRILL, supra note 29, at 207 n.2.
34. See, e.g., 6 Fed. Reg. 5921, 5925 (Nov. 22, 1941); 6 Fed. Reg. 3304, 3310 (July 8,
1941); 5 Fed. Reg. 3565 (Sept. 5, 1940).
35. See William W. Goodrich, The Coming Struggle over Vitamin-Mineral Pills, 20 Bus.
LAW 145 (1964). Mr. Goodrich was, at the time he wrote his article, the Chief Counsel for the

FDA.
36. 27 Fed. Reg. 5815 (June 20, 1962).
37. See Goodrich, supra note 35, at 147.
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required doses in excess of that needed to avoid clinical deficiencies."
They resisted the FDA's regulatory effort with fervor. The final
regulations, issued in 1973 after a long administrative hearing, prohibited irrational combinations of vitamins and minerals when sold as foods,
and set the maximum and minimum potency of the recognized food
nutrients.39 In addition, high doses were to be considered drugs under
the drug definition, even in the absence of any explicit drug claim by
the manufacturer, because of the lack of any nutritional need for a
higher dose.'
On judicial review, the agency won a partial, temporary victory.
Judge Friendly found that the agency had the authority to protect
consumers from confusion about the food value of supplements by
limiting combinations and doses of vitamins and minerals." Consumers
who wanted nutrients above the levels set by the regulations were not
prohibited from ingesting more; they could simply "take as many more
tablets" as they liked.42 The court remanded the regulations, however,
for further consideration of exceptions and changes in some of the
dosage levels.43
With respect to the classification of high-dosage nutrients as drugs,
the court found that a product is a drug only if the manufacturer intends
its use for drug purposes.' A manufacturer's actual intent could be
determined on the basis of "objective evidence," and a factfinder was
not bound by a manufacturer's subjective claims.45 More was needed
to show an actual therapeutic intent based on objective evidence,
however, than a mere lack of nutritional usefulness, the basis relied on
by the FDA.46 Indeed, the court recognized that some consumers have
particularly high nutritional needs.47
Following the decision and the FDA's victories on points of legal
theory, supplement manufacturers and users were "outraged" and

38. See National Nutritional Foods Ass'n v. FDA, 504 F.2d 761, 789, 791 (2d Cir. 1974).
39. See 38 Fed. Reg. 20,708, 20,730 (1973).
40. See id.
41. See National NutritionalFoods, 504 F.2d at 789-92.
42. See id. at 792.
43. See id. at 808.
44. See id. at 789.
45. See id. The determination of the manufacturer's intent also can be found in labeling,
promotional material, advertising, and other material for which the promoter is responsible. See
United States v. Sudden Change, 409 F.2d 734, 739 (2d Cir. 1969).
46. See NationalNutritional Foods, 504 F.2d at 789.
47. Id. The petitioners also maintained that there was a "fairly widespread if minority
belief that the 'optimal' level of nutrition" was higher than the levels set by the FDA to avoid
clinical deficiencies. Id. at 791.
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lobbyed Congress for a change. 8 Congress responded by enacting the
"Proxmire amendment," which revoked the FDA's authority to regulate
vitamins and minerals as foods based on irrational combinations or
potency limits.49 In addition, the FDA could not classify a vitamin or
mineral as a drug "solely because it exceeds the level of potency which
[the FDA] determines is nutritionally rational or useful."5
The FDA responded by seeking to regulate some supplements on the
basis of what remained of its authority under the judicial precedent,
notwithstanding the legislative amendment. The FDA sought to show
that high doses of Vitamins A and D were drugs based on objective
evidence of manufacturer's intent, not because of their lack of nutritional usefulness, but because the promotion of those vitamins by others had
led to such widespread therapeutic use by consumers that such use
outweighed their use as dietary supplements." On review, the court,
with a different panel, found the evidence of intent insufficient because
the FDA had not shown that consumer use for therapeutic purposes
corresponded to the particular dosage level which the FDA had used to
classify the vitamins as drugs-a level that the FDA had based on safety
considerations. 2 Some consumers used lower levels for drug purposes;
some used higher levels based on their views of the nutritional value at
that level.53 The court demanded a high standard of proof to show
objective intent: the use must be widespread and involve use of the
particular dose level by the consumer for a knowing therapeutic use, and
not simply consumer use for a nutritional purpose that experts might
regard as mistaken and confused.' The interpretation was in line with
the broader impact of the Proxmire amendment in making it harder for
FDA to classify supplements as drugs.55

48. Mark A. Kassel, From a History of Near Misses: The Future of Dietary Supplement
Regulation, 49 FOOD & DRUG L.J. 237, 257 (1994).
49. See 21 U.S.C. § 350 (1994) (originally enacted 1976).

50. Id. § 350(a)(1)(B).
51. National Nutritional Foods Ass'n v. Mathews, 557 E2d 325, 329 (2d Cir. 1977).

52. See id. at 337-38.
53. See id.
54. See id.
55. A larger significance of the Proxmire amendment was suggested by Judge Friendly
in a related case when the FDA tried to re-issue certain aspects of its food supplement
regulations that had been remanded in NationalNutritionalFoods, 504 F.2d at 761. The court
found that Congress was not concerned about the risk of consumer confusion over food issues
that had been the basis for the original regulations, or, at least, that Congress considered the
costs "too high" in relation to the benefits. While the FDA still had the legal authority to issue
the particular regulations, the court required the agency to take further public comment on
whether there was a sufficient consumer need for them. See Kennedy, 572 E2d at 385. In the
end, the FDA withdrew the entire regulatory scheme.
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C. Scaled-Back Enforcement and Expansion
of Supplement Uses
After the Proxmire amendment, the FDA scaled back its enforcement
efforts with respect to supplements. The amendment and the court
decisions "dissuaded the agency from routinely regulating these
products."56 Under its food authority, the FDA would enforce the
requirements for pre-market approval of the safety of a food additive
when a specific safety concern arose, rather than because of the lack of
information about the supplement. The agency brought enforcement
action under its drug authority when the labeling "contained" unauthorized drug claimsY
This policy of restraint made it easier for additional types of products
to be sold as supplements, resulting in a significant expansion in the
number of supplements on the market by the 1990s." Shark cartilage
and herbs used in traditional medicine joined the vitamins and minerals
in the health food stores. The FDA would not take enforcement action
against, these new types of supplements unless there were identified
safety concerns, or unless the manufacturer made express drug claims
in labeling or promoted the products as drugs through advertisements or
other means. 9
The availability of these products permitted "off-label" uses by
consumers.' Popular literature, books, or other sources might identify
the supplements as having a disease treatment value not suggested in the
labeling. Some consumers might also know from their own experience
of traditional therapeutic uses. Thus, consumers could use these products
for medicinal purposes, but the manufacturers would face enforcement
56. General Accounting Office Report to Senator Kennedy, at 4 (B252966, July 2, 1993),
reprinted in 1. SCOTr BASS & ANTHONY L. YOUNG, DIETARY SUPPLEMENT HEALTH AND
EDUCATION ACr: A LEGISLATIVE HISTORY AND ANALYSIS 297, 300 (1996).
57. Id.
58. FDA Advance Notice, 58 Fed. Reg. at 33,698-99 (1993). Congress required the FDA
to revoke this notice but it remains of historical value. See infra text at pt. III.B.I.
59. See General Accounting Office Report, supra note 56.
60. The term "off-label use" is a common informal reference to the use of an approved
drug by a physician for a use not approved by the FDA, which raises issues analogous to
consumer use of dietary supplements for unapproved purposes. The physician's use of the drug
for this extra-label use as part of the practice of medicine is not prohibited by law. See Legal
Status of Approved Labeling for PrescriptionDrugs; Prescribingfor Uses Unapproved by the
Food andDrug Administration, 37 Fed. Reg. 16,503, 16,503-04 (1972); Richard A. Merrill, The
Architecture of Government Regulation of Medical Products, 82 VA. L. REV. 1753, 1853-57
(1996). Under the 1997 drug reform law, for the first time the manufacturer can refer to
scientific studies about the off-label uses under certain conditions. See § 402, 111 Stat. at 236566 (to be codified as amended at 21 U.S.C. ch. V, subch. E); see also discussion infra pt.
HI.D.2.a.
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action by the FDA in practice only if there were express drug claims
that could be attributed to the manufacturers.
D. The FDA's Renewed Scrutiny of Supplement Safety and
Uses and the CongressionalResponse
The FDA reviewed this policy in 1993 in the wake of the 38 deaths
and 1500 adverse effects attributed to L-tryptophan, an amino acid sold
as a dietary supplement and widely used and promoted for body-building." Amino acids are the "individual structural units of proteins" and
may be precursors for neurotransmitters and hormones. 2 The consumption of protein in foods ordinarily supplies sufficient amounts of amino
acids. 3 In an Advance Notice of Proposed Rulemaking (FDA Advance
Notice), the FDA described an FDA Task Force recommendation that
amino acids be regulated as drugs because of information that their
"primary intended use.., is for therapeutic rather than nutritional
purposes," and because of the "wide marketing" of these products for
disease prevention and treatment purposes.' The FDA found that many
amino acids clearly were being marketed in violation of the law because
they were unapproved food additives. 5 The FDA invited comment on
its intent to bring the amino acids into compliance with the law.'
The FDA also found that many herbs sold as supplements have "no
known history of food use and, even without drug claims are used for
medical purposes" and as traditional medicines.67 The FDA indicated
that its immediate goal was consumer safety, but also stated that "many
herbal products are marketed for drug uses," and would be the subject
of regulatory action based on the FDA's health fraud policy.6
The FDA also recognized an additional "other" category of supplements. 9 These included substances found in plant and animal products,
such as fish oils and fibers, many of which have no nutritive value.7"
The FDA asked for comments on whether it should continue its policy
of regulating these substances as foods.7

61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.

See FDA Advance Notice, 58 Fed. Reg. at 33,695-66.
Id. at 33,695.
Id.
Id. at 33,697.
Id.
Id.
Id.
Id. at 33,698.
See id.
See id.
See id. at 33,699.
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The FDA Advance Notice set off a controversy. Although the notice
made some references to how the supplements were marketed and
promoted, the FDA was seen as attempting to revive its earlier failed
effort to classify high-dosage vitamins as drugs based upon widespread
consumer use, in the absence of express drug claims by the manufacturer.72 The application of the food additive provisions to amino acids, as
suggested by the FDA Advance Notice, would effectively remove many
of these supplements from stores, since "adequate scientific evidence to
ensure" their safe use "did not exist. . .7" A "national blackout day"
was organized, and products that were the "target" of the FDA Advance
Notice were "draped in black so that consumers could 'see' what would
be taken away."'74 The FDA's Commissioner Kessler tried unsuccessfully to alleviate concerns by stating in Senate testimony that "any
nutritionalsupplement currently on the market can be sold so long as
it presents no safety problem."75 The consumer reaction to the FDA
Advance Notice had already "galvanized support" for the legislative
efforts that led to DSHEA.76
E. Health Claims, Dietary Supplements,
and the Enactment of DSHEA
Another factor that contributed to the enactment of DSHEA was the
FDA's 1994 decision that no dietary supplements then had the support
needed to make health claims to help prevent disease, and that no lesser
standard should be used for supplements than that applicable to
conventional foods.7 7 At one point, the FDA regarded any disease
prevention claim on food to be a drug claim needing approval under the
new drug procedures.78 That policy changed when the FTC accepted
the appropriateness of advertisements about the value of consuming
high-fiber foods in preventing cancer, a value recognized by the
National Cancer Institute (NCI).79 The FDA started a rulemaking
proceeding to determine the support needed by food manufacturers

72. See COMMISSION REPORT, supra note 16, at 13; Mathews, 557 F.2d at 325.
73. FDA Advance Notice, 58 Fed. Reg. at 33,697.
74. BASS & YOUNG, supra note 56, at 28.

75. Legislative Issues Related to the Regulation of Dietary Supplements: Hearingsof the
Senate Comm. on Labor and Human Resources, 103 CONG. 19 (1993) (emphasis added).
76. See BASS & YOUNG, supra note 56, at 7.
77. See 59 Fed. Reg. 395 (1994) (adding 21 C.FR. § 101.4).
78. See Htrr & MERRILL, supra note 29, at 180.
79. See Peter B. Hutt, Health Claims for Foods-An American Perspective, Kellogg
Nutrition Symposium, Toronto, Can. (Apr. 1986), reprintedin HuTr & MERRILL, supra note 29,
at 183.
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seeking to make health claims."° While the rulemaking proceeded,
manufacturers continued to make health claims for products that
engendered controversy. Congress resolved the debate by enacting the
Nutrition Labeling and Education Act of 1990 (NLEA),8" which
authorized health claims for foods but required that such claims be
based on well-designed studies and significant scientific agreement. 2
In addition, prior approval by the FDA was required in the form of a
regulation governing the type of claim. 3
Congress also authorized the FDA to establish a separate procedure
and standard applicable to dietary supplements of nutritive value.84
Notwithstanding this authorization to treat supplements differently, the
FDA decided that the same standards should apply to health claims on
both foods and dietary supplements. Under the standards, as applied by
the FDA at that time, some conventional foods but no dietary supplements qualified to bear health claims on their labels.85 The inability of
dietary supplements, in practice, to meet the standard for health claims
established in the NLEA for conventional foods contributed to the push
that led to the enactment of DSHEA.
II. IMPACr OF DSHEA AND EXPANDED
OPPORTUNITIES FOR CLAIMS

DSHEA redrew the boundary between drug and dietary supplement
claims, but that boundary is ambiguous on several points. DSHEA
defined dietary supplements, gave manufacturers the right to make a
new type of claim about the effects of the supplements, exempted
certain publications from being regarded as labeling, exempted dietary
supplements from being treated as food additives, and provided for reexamination of how health claims for supplements should be regulated.
The more notable features of and issues concerning DSHEA are
addressed below.
A. Health Claims
1. DSHEA Provisions
The DSHEA provisions on health claims are distinct from-but have
influenced-the developments that led to DSHEA's provisions on other
80.
81.
82.
83.
84.

See
See
See
See
See

52 Fed. Reg. 28,843 (1987).
Pub. L. No. 101-535, 104 Stat. 2353 (1990) (adding 21 U.S.C. § 343(r)).
21 U.S.C. § 343(r)(3)(B)(i) (Supp. V 1993).
id. § 343(r)(3)(A)(ii).
id. § 343(r)(5)(D).

85. See BASS & YOUNG, supra note 56, at 15.
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labeling claims.8 6 While Congress was concerned about the inability of
dietary supplements to qualify for health claims, Congress did not
change the legal standard governing the claims for supplements. Instead,
Congress directed the Commission created by DSHEA to consider the
appropriate standard and report its recommendations with respect to the
FDA regulations that determined that the same standards that apply to
ordinary foods should apply to supplements. 7
2. Commission Action and Analysis
After considering the matter, the Commission recommended that
significant scientific agreement and regulatory approval by the FDA
should apply to health claims on both dietary supplements and conventional foods.8" Applying the same standard serves the interest of
fairness in ensuring a level playing field and helps prevent consumer
confusion. 9 Some supplements also have now qualified to bear health
claims.'
The Commission recommended that the FDA permit more involvement by outside expert reviewers in the FDA review process without
making the views of the experts presumptive.9 Under this approach,
the FDA is to identify the criteria for determining whether reviews by
outside experts will be scientifically qualified, balanced, reliable, and
independent.92 Submissions from a panel meeting the criteria would
86. See discussion infra pt. III.C.1.
87. See § 12, 108 Stat. at 4332-33. The FDA was required to issue regulations in response
to any Commission recommendation for a regulatory change, and if the FDA did not act on a
timely basis, dietary supplements would have been exempt from the requirements of the NLEA.
See id.
88. See COMMISSION REPORT, supra note 16, at vii & 31.
89. See id. at 34. The need to have adequate testing of the supplement is illustrated by the
results of a National Cancer Institute (NCI) study that had aimed to determine whether beta
carotene supplements would reduce the risk of cancer in smokers because of the antioxidant
qualities of the vitamin. See Gina Kolata, Studies FindBeta Carotene, Used by Millions, Doesn't
Forestall Cancer or Heart Disease, N.Y. TIMES, Jan. 19, 1996, at A16. Those receiving the
supplement actually had higher incidence of cancer, and the NCI ended the study before
completion because of the possible adverse effects from the supplement. See id. This study
indicates that the pill can, indeed, be different from the food, and that studies are needed on the
supplement itself to determine its benefits.
90. See COMMISSION REPORT, supra note 16, at 33 tbl. 2 (Approved Health Claims for
Dietary Supplements and Conventional Foods).
91. See id. at 35.
92. See id. at vii-viii & 35 (recommending that the FDA ensure broad input, including
from scientists outside the agency and from other governmental agencies, to determine the
degree of scientific agreement existing for each health claim). The development of appropriate
criteria is an important and difficult task. See Margaret Gilhooley, The Administrative
Conference and the Progress of Food and Drug Reform, 30 ARIZ. ST. L.J. 129 (forthcoming
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strengthen the petition and expedite the review process. In recent
legislation, Congress has provided for additional expert input by
authorizing health claims for foods or supplements based on "an
authoritative statement" of the National Academy of Sciences (NAS) or
of a scientific health agency of the government, unless the FDA
provides otherwise through rulemaking.93
There have been constitutional challenges to the statutory requirement for FDA approval of health claims. A time deadline for FDA
action on final rules concerning health claims has been found to be
necessary, but the regulatory scheme has otherwise not been found to be
constitutionally infirm.94
B. Definition and Availability of Dietary Supplements
1. DSHEA Provisions
Congress has now defined "dietary supplement" as a product
"intended to supplement the diet that... contains one or more of the
following dietary ingredients: (A) a vitamin; (B) a mineral; (C) an herb
or other botanical; (D) an amino acid; [or] (E) a dietary substance for
use by man to supplement the diet by increasing the total dietary

1998); Merrill, supra note 60, at 1858.
93. 21 U.S.C. § 343(r)(3)(C) (as added by § 303, 111 Stat. at 2350-51). There are
provisions for making rules effective upon publication. 21 U.S.C. § 343(r)(7) (as added by §
301, 111 Stat. at 2350-51).
The Commission recommended only that the FDA give considerable weight to the
recommendations of other government agencies in determining whether significant scientific
agreement exists for a health claim. COMMISSION REPORT, supra note 16, at iv & 36.
An NAS report for a federal agency was recently found to be subject to the Federal
Advisory Committee Act (FACA), 5 U.S.C.A. 2 § 5(b) (1994). See Animal Defense Fund, Inc.
v. Shalala, 104 F.3d 424, 431 (D.C. Cir.), cert. denied, 118 S.Ct. 367 (1997). Congress has
since provided that the FACA does not apply to the NAS, but for an agency to make use of the
reports, there must be balance on the committees, safeguards against conflict of interest, and
publication of the names of proposed members. See Nicholas Wade, Science Advisers Retain
Independence but Must Be More Open, N.Y. TIMES, Nov. 16, 1997, at 23.
94. See National Council for Improved Health v. Shalala, 122 F.3d 878 (10th Cir. 1997)
(finding lack of standing); Nutritional Health Alliance v. Shalala, 953 F. Supp. 526, 530
(S.D.N.Y. 1997).
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intake... ,95 The supplements are "deemed" foods, except when they
are intended for a use covered by the drug definition.96
The new definition parallels the categories discussed in the FDA
Advance Notice, and seems to be a reaction to the theories raised by the
FDA about the factors that could lead to drug status. Indeed, Congress
declared the Advance Notice to be "null and of no effect insofar as it
relates to dietary supplements" and the FDA was directed to revoke the
notice.97
The definition of supplements as "dietary" indicates that the supplements should have a biological basis, in the sense that they are derived
from natural products (such as herbs and botanicals), are the same as
substances found in foods (such as vitamins and minerals), or are
physically needed substances derived from foods (such as amino acids).
2. Analysis
While dietary supplements have to be intended to supplement the
diet, the meaning of "dietary" is not stated. In describing structure and
function claims, DSHEA refers to both "dietary ingredients" and
nutrients, indicating that supplements need not be nutrients.9" In light
of this provision, the definition and the statutory rejection of the
Advance Notice, herbal supplements labeled simply as dietary supplements, without any disease-related labeling claims, should not be
considered drugs merely because they contain nonnutritive ingredients,
or lack a history of food use. Herbal supplements will be governed by
the same demanding tests that have applied in establishing whether
nutritive supplements are drugs.9 9 Thus, any effort to show that herbs
are drugs, based on objective factors, will depend upon establishing the
level at which consumers use the product for a drug purpose rather than
a "dietary" one. Congressional rejection of the FDA Advance Notice
indicates a concern with the availability of supplements, and suggests

95. See § 3, 108 Stat. at 4327 (enacting as amended 21 U.S.C. § 321(ff)). By definition,
a dietary supplement cannot include a substance that is the subject of a new drug application or
an investigational new drug application, without the FDA's permission. Id. As a result, a
botanical version of an approved drug, such as Taxol, could not be sold as a supplement without
FDA permission. See Robert G. Pinco & Paul D. Rubin, Ambiguities of the Dietary Supplement
Health and Education Act of 1994, 51 FOOD & DRUG L.J. 383 (1996) (discussing uncertainties
concerning whether a hormone, such as melatonin, is a dietary substance).
96. See id.
97. § 11, 108 Stat. at 4331.
98. See 21 U.S.C. § 343(r)(6); discussion infra pt. III.C.
99. See discussion supra pt. II.B. The Commission recognized that, under DSHEA,
botanical products should continue to be marketed as dietary supplements when properly labeled.
COMMISSION REPORT, supra note 16, at 57.
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that a strong showing is needed to establish drug intent in the absence
of express manufacturer's claims." Congress did not expressly alter
the tests for determining drug intent, though, and the objective test for
determining a manufacturer's intent presumably remains a potential
basis for determining intent, but one that is difficult to satisfy.
To meet the demanding showing, the agency could seek to show that
consumers use a supplement solely for drug purposes. The sale of bear
parts as a "dietary supplement" without any other claims might provide
an example of such an extreme case, given the use of bear gall and
other parts in traditional medicine.'0 ' Widespread consumer use would
have to be particularly strong to outweigh the dietary use if it is to be
considered sufficient to establish the manufacturer's intent in the
absence of other factors.
The expansive approach to the basis for determining a
manufacturer's intent, upheld in the litigation over the FDA's rule
regulating tobacco,'" provides support for giving consumer use greater
effect in determining the manufacturer's intent concerning the use of
certain types of products. Tobacco products contain nicotine, which has
a discernible physical effect, that is addictive. This effect makes it
possible to show that manufacturers can reasonably foresee that
consumers will recognize and use the product for its drug effects. Some
supplements can have marked physical effects, such as high doses of
stimulants, anti-depressives or substitutes for narcotic-type drugs, like
herbal ecstasy. Through use, the consumers can recognize the effects of
the supplements as ones that relate to disease or drug-like effects, even
if the use is not addictive. In these situations, there is a similar basis for
maintaining that the manufacturer should foresee that consumers will
recognize the effects through experience and use products containing
potent doses as a drug even when the use is not stated on the label.
A different question arises when a manufacturer of a dietary
supplement makes an express claim. The claim itself may suggest use
to prevent or treat disease or a non-dietary use and needs careful
examination. 3

100. See discussion supra pts. ll.D. & III.A.1.
101. See Tom Johnson, Senate Moves to Shield Wildlife from the Claws of Poachers,THE
STAR-LEDGER, Mar. 11, 1997, at 1 ("Bears are highly sought as aphrodisiacs or tonics in Asian
medicinal shops, where their gall bladders fetch as much as $1,000 each.").
102. See Coyne Beahm, Inc. v. FDA, 966 F. Supp. 1374 (M.D.N.C. 1997). The FDA rules
are in 61 Fed. Reg. 44,396 (1996) (to be codified at 21 C.FR. pt. 897).
103. See discussion infra pt. III.C.2.b.ii.
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C. Statements of Nutritional Support
and Structure/FunctionClaims
1. DSHEA Provisions and Scope
DSHEA provides an important new opportunity for dietary supplements to make "statements of nutritional support"-the title for this
section of DSHEA when enacted-without the claim being considered
a drug claim." These statements can describe "the role of a nutrient
or dietary ingredient intended to affect the structure or function in
humans," or describe "general well-being from consumption of a
nutrient or dietary ingredient."10 5
DSHEA imposes some significant limits on these statements. The
statements must be substantiated and cannot be misleading. The products
must also bear the disclaimer, "This statement has not been evaluated
by the Food and Drug Administration. This product is not intended to
diagnose, treat, cure, or prevent any disease."'" The list parallels the
drug definition.1 7
Some of those involved in the legislative debate over DSHEA
apparently viewed the authorization of statements of nutritional support
as a "trade-off' under which NLEA was left in place to regulate health
claims concerning the relationship between disease and foods and
nutritive supplements. In return, structure and function claims could be
made for dietary supplements, without the supplements being subject to
the drug law, even if the effects were not those of a nutrient."°
To understand how structure and function claims have expanded the
ability to make drug claims, some background is needed about the scope
of the drug definition and the traditional boundaries between foods and
drugs. An article can be a drug not only because its label makes disease
prevention and treatment claims, but also because it claims to affect the
structure and function of the body, such as by helping to reduce
weight." Foods have always been statutorily excluded from this
provision, since otherwise their very effect in providing sustenance
104. See § 6, 108 Stat. at 4329.
105. 21 U.S.C. § 343(r)(6). The statements also can relate to classical nutrient deficiency
disease, but the "structure or function" claims are the most important and far-reaching in their
potential scope.
106. 21 U.S.C. § 343(r)(6)(C).
107. See 21 U.S.C. § 321(g) (1994) (stating that a drug means articles "intended for use
in the diagnosis, cure, mitigation, treatment, or prevention of disease."). The two most important
categories, drug prevention and treatment, are used as shorthand in this Article to refer to the
various uses that establish a disease claim.
108. See BASS & YOUNG, supra note 56, at 53, 55.
109. See 21 U.S.C. § 321(g).
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would make them drugs. To gain the benefit of this exclusion from the
drug testing requirements, some unconventional products have claimed
to be foods, leading to the need for court determinations of what makes
something a food.
A leading case interpreted the food definition on a "common sense"
basis as covering articles primarily used for "taste, aroma, or nutritive
value."'1' A product sold as a "starch blocker" was a drug rather than a
food under this test, as it was claimed to block digestion to prevent
weight gain, a use that did not provide nutrition."'
DSHEA now authorizes "statements of nutritional support" on dietary
supplements for both nutrients and "dietary ingredients," and exempts
the statements from the drug provisions.12 Claims are, thus, now
exempt from the drug provisions not only when they relate to substances
of nutritive value, but also when they are "dietary" in some other sense.
Moreover, the definition of dietary supplements in DSHEA encompasses
herbs and botanicals and other "dietary" substances, some of which may
have no history of food use. The potential reach of structure and
function claims becomes clearer when one considers that many claims
recognized by the FDA as OTC drug claims are structure and function
claims rather than disease claims. Thus, the OTC review covers claims
for sedatives, stimulants, laxatives, some contraceptive products, and
miscellaneous
products, a category broad enough to include aphrodisi3
acs.1
As a result of the authorization of structure and function claims in
DSHEA, an increased number of claims are being made for supplements, particularly herbal supplements, that would not have qualified for
exemption from the drug provisions under the earlier judicial test. The
FDA has been notified of over 1000 such claims, including that ginkoba
"improves memory and concentration" and "enhanc[es] your mental
focus," that saw palmetto "maintain[s] prostate health and well-being,"
that milk thistle "nutritionally supports healthy liver function," that
echinacea "helps promote general well-being during the cold and flu
season" and "supports healthy immune function," that ginseng provides
"stress support" and "gives active adults a competitive edge," that

110. See Nutrilab, Inc. v. Schweiker, 713 F.2d 335, 338 (7th Cir. 1983). Because the test
focused on the primary use of the substance, coffee and prunes were not considered drugs
because of the occasional consumer use to affect bodily functions. See id.
Another court considered claims about lipotropic properties to be drug claims. See United
States v. Vitasafe Formula M, 226 F.Supp. 266, 278 (D.N.J. 1964).
111. See id. at 338-39.
112. See 21 U.S.C. § 321(g); 21 U.S.C. § 343(r)(6) (emphasis added). The term "statements
of nutritional support" was used as the heading in the statute as enacted. § 6, 108 Stat. at 4329.
113. See 21 C.F.R. § 330.05 (1997).
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melatonin is "produced in the pineal gland... and aids in the regulation
of circadian rhythms," and that valerian "Night Time" has substances in
nervous system activity which can be
the root that "slow the' central
4
evening."
helpful in the
The FDA has not taken a position on many claims for which it has
received notices, but this does not necessarily indicate concurrence." 5
When the FDA does object to a claim, the manufacturers may revise
their claims to make more general statements of well-being, or claims
for general support of bodily functions. Thus, there may be a continual
generation of claims that test the scope of permissible statements of
nutritional support. The FDA also has recognized that there are gray
areas where it is unclear whether claims are appropriate structure and
function claims or whether they are drug claims." 6 While there is a
need for further guidance concerning the line between nutritional support
claims and inappropriate drug claims, providing guidance with respect
to these matters is a daunting task.
2. Analysis
Congress has enacted an enigma in this provision of DSHEA.
Statements of "nutritional" support are now permitted concerning the
effects of "dietary" ingredients on the structure and function of the
body, even though the ingredients are not nutrients, and lack the other
characteristics of taste and aroma used in the past to identify foods. At
the same time Congress has failed to identify what makes something a
"dietary" ingredient. Conceivably, at one extreme, one might think
Congress intended "dietary" to include any biological substance that can
be ingested, and that statements of nutritional support can cover any
non-therapeutic effect the substance may have. If so, Congress gave
"dietary" a meaning beyond its normal one since the dictionary
definition of dietary reflects a "food" meaning." 7 If Congress intended

114. See Dietary Supplement Statements of NutritionalSupport, THE TAN SHEET, Jan. 15,
1996, at 11-15. Under 21 U.S.C. § 343(r)(6), the FDA must be notified of such statements, but

no prior approval by the FDA is needed.
115. See Labeling: Current Issues and Policy Decisions, 39th Annual Educational
Conference, Food and Drug Law Institute (Dec. 12, 1995) (speech by F. Edward Scarbrough).
116. See id.
117. Webster's Dictionary defines "dietary" as "of or related to a diet," and "diet" as "food
and drink regularly provided or consumed." WEBSTER'S THIRD NEw INTERNATIONAL
DICrIONARY 629 (1963); see Proposed Rule, Dietary Supplements Containing Ephedrine
Alkaloids, 62 Fed. Reg. 30,678,30,699 (1997) [hereinafter ProposedRule, DietarySupplements];
infra pt. III.C.2.b. for discussion of the FDA's interpretation of "dietary" based on dictionary
definitions of "food." The FDA cited Webster's Dictionary definition of "diet" as " 'an
organism's usual food and drink' " and Dorland's Medical Dictionary definition as "'the
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a narrower meaning, it did not indicate what the parameters were apart
from the word "dietary" itself. There is virtually no legislative history." 8 The interpretation of DSHEA, thus, presents a challenge. 9
Determining what dietary claims are appropriate involves considering
interrelated factors about what makes a claim a disease claim, a dietary
claim, or a prescription claim. Since statements of nutritional support
cannot by law be disease claims, identifying disease claims is a critical
first step in analysis.
a. Identifying Disease Claims
While DSHEA precludes disease claims on supplements, there is
debate about what constitutes a disease claim. Some believe that only
express claims are barred, and that implied disease claims are permissible because of congressional concern with health promotion, as expressed in the findings for DSHEA. n° On the other hand, the drug
provisions have long applied to implied disease claims that would
''create in the mind of the public" the idea that a product can be used
for disease prevention or treatment.' 2 ' A claim that a supplement
would "promote non-suicidal feelings" should be regarded as a claim to
prevent or treat depression even if the word "depression" were not
mentioned. The health needs of the public can be adversely affected if
products can imply usefulness in forestalling disease when the products
customary allowance of food and drink taken by any person from day-to-day..... 62 Fed.
Reg. at 30,699. According to the FDA these definitions suggest that "diet is composed of usual
food and drink that may be designed to meet specific nutritional requirements." Id.
118. See 140 CONG. REC. Hl180 (daily ed. Oct. 6, 1994) (Statement of Agreement); 140
CONG. REC. S14801 (daily ed. Oct. 7, 1994). The Statement specifies that it is "the entire
legislative history for DSHEA." Id.
119. Statutory interpretation is to begin with the text of the statute as the primary source
for determining Congress' intent. See Chevron, U.S.A., Inc. v. Natural Resources Defense
Council, Inc., 467 U.S. 837, 842-43, reh'g denied, 468 U.S. 1227 (1984). In the absence of clear
congressional intent, the courts will defer to a reasonable agency interpretation. See id. at 84344. The Supreme Court will, at times, consider other sources in determining congressional intent,
including the legislative history, the statutory framework, and the purpose of the statute. See
Babbitt v. Sweet Home Chapter, 515 U.S. 687, 708 (1995).
120. See COMMISSION REPORT, supra note 16, at 36; § 2, 108 Stat. at 4325-26 (finding that
"the importance of nutrition and the benefits of dietary supplements to health promotion and
disease prevention have been documented increasingly"). Some members suggested that a claim
that a supplement would affect immune function or resistance should be a "legitimate" claim of
nutritional support, notwithstanding that the FDA has historically been sensitive that claims
relating to immune function imply use in the treatment of AIDS. See COMMISSION REPORT,
supra note 16, at 36.
121. United States v. Fairfax Cigarettes, 113 F. Supp. 336, 338 (D.N.J. 1953); see United
States v. 'Line Away Temporary Wrinkle Smoother, Coty', 415 E2d 369, 372 (3d Cir. 1969)
(finding that implied claims that a product was a pharmaceutical made the product a drug).
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do not have the level of support and review ordinarily required for
drugs.
Once it is accepted that implied disease claims are not permissible,
there can still be difficulties in determining when a claim is sufficient
to constitute an implied disease claim. Claims for supplements often
take the form of a statement that the supplement promotes or supports
the health of an organ of the body, without expressly stating that the
supplement helps prevent the organ from becoming diseased.
The Commission report recognized a difference between claims to
correct a function and claims to maintain a function." Under this
guidance, statements to "restore" a normal, or "correct" an abnormal,
function of the body should not be made when they relate to an
abnormality that suggests the presence of disease, such as a claim to
"restore" normal blood pressure when the abnormality implies hypertension." Claims to maintain or support a body system, organ or function can be appropriate, depending upon the context, when the statement
does not suggest disease prevention or treatment or use for a serious
health condition beyond the ability of the consumer to evaluate. 24 In
the report, some Commission members indicated they were "troubled"
by references to specific organs, and found the "most problematic"
wording relates to references to organs such as the heart, liver, or
prostate, which are "associated with major clinical conditions.""t
On analysis, the factors discussed in the Commission report indicate
the relevance of the need for medical advice in helping to identify an
inappropriate supplement claim and a disease-related claim. A claim to
stimulate or maintain heart function is an example of a claim beyond the
role of the consumer to evaluate, and one that calls for medical advice.
Such claims are more likely to be viewed by the users as related to
disease.
The FDA has taken the position in connection with "herbal fen
phen" products that they are unapproved drugs because the name and
claims reflect that they are intended for the same use as prescription
drugs which have been withdrawn from sale because of safety concems. 26 Claims for substitutes for prescription drugs are particularly
122. See COMMISSION REPORT, supra note 16, at viii, 38-39.
123. See id.
124. See id.
125. See id. at 36-37.
126. See FDA Warns Against Drug Promotion of "Herbal Fen-Phen," FDA TALK PAPER,
T97-56 (Nov. 6, 1997), available at http:llwww.fda.gov/bbs/topics/ANSWERSIANS00832.html;
FDA Warns ConsumersAbout Herbal Weight Loss Mixtures, N.Y. TIMES, Nov. 7, 1997, at AI9
(" It is illegal ... to call this product something that is exactly like a medication and to make
medical claims that it will cause weight loss and treat obesity, like the prescription products
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troubling because they are likely to involve effects or conditions beyond
the ability of the consumer to evaluate. 27 While non-prescription
claims also can be disease claims, the need for medical advice and a
prescription can be especially useful in identifying implied disease
claims."
A claim to lower high blood cholesterol levels, not through diet but
through use of an isolated ingredient, provides another example of a use
for which medical advice has been considered necessary and one that
can imply a medical use to consumers.'29
b. Identifying "Dietary" Claims
i. Health Promotion and Preclusion of
Herbal Ecstasy
The FDA maintains that, under the definition, dietary supplements
are intended to supplement the diet, and that the congressional findings
in DSHEA suggest that Congress intended supplements "to augment the
diet to promote health and reduce the risk of disease." 1" Accordingly,
claims for recreational effects, such as being a substitute for illicit street

do"); "Cholesterol-Lowering Drugs 'Should Not Be Sold OTC' in the U.S., FDA states," TiE
PINK SHEET, T&G 7, Oct. 13, 1997.
127. See, e.g., Sandra G. Boodman, Now That Two PopularWeight-Loss Drugs Are Off the
Market, What's Left for Dieters?, WASH. POST, Sept. 16, 1997, at Z12 (reporting that some
"programs are touting their use of so-called 'herbal' or 'natural' fen/phen," made up of ephedra
and St. John's wort, a supplement popular in Europe for treating mild depression).
128. See discussion infra pt. III.2.c.
129. See FDA Seeks Pharmanex Citizen Petition Request, THE TAN SHEET, Oct. 13, 1997,
at 1 (FDA letter finding claims that Cholestin reduces cholesterol levels to be disease claims).
The issue also tests the scope of the definition of "dietary supplements" and its exclusion of
articles covered by a new drug application (NDA) absent an FDA exemption. See 21 U.S.C. §
321(ff)(3). Cholestin contains an ingredient like that in a prescription drug which has an
approved NDA. See Cholestin "Designedto Be Differentfrom Red Yeast Rice Merck Argues in
Comments, THE TAN SHEET, Feb. 9, 1998, at 17 (Merck maintains the product is "designed
as ...a generic alternative to Mevacor."). In a letter, the FDA has found that the product is a
drug, and that it would "not be fair" to the NDA-holder if differences in purity and inactive
ingredients made the product a dietary supplement. See Lovastin Content Renders 'Cholestin'
an Unapproved New Drug, THE PINK SHEET, T&G 8, Oct. 13, 1997.
Some Commission members indicated that well-crafted claims relating to cholesterol levels
would, in their view, be appropriate structure and function claims. See COMMISSION REPORT,
supra note 16, at 37.
130. Proposed Rule, Dietary Supplements, 62 Fed. Reg. at 30,678; 21 C.ER. pt. 111
(1997); see also Committee Reviews Evidence that EphedraIs More Drug than Food orDietary
Supplement, FOOD CHEMICAL NEWS, Sept. 9, 1996, at 9-10 (statement of Food Advisory
Committee Meeting, Aug. 27, 1996) (" 'In China, [ephedra] is always used to treat diseases, not
as a food.... This does not have any value in terms of diet.").
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drugs, are drug claims, and not claims to supplement the diet. The FDA
relied on the common sense meaning of "diet" as well as the dictionary
definitions that relate to "customary" or "usual" uses of food and
drink.' This approach recognizes the need for a dietary connection
for dietary supplements, links it to health factors and disease risk
reduction, and excludes supplements that claim narcotic-like effects,
such as herbal "ecstasy." The FDA did not indicate how to identify
disease risk reduction factors without implying disease prevention.
Presumably, it relates to the generality of the dietary claim, and the
identification of a physical effect without suggesting disease prevention.
ii. Statements of Nutritional Support: The Need
for a Dietary Relationship and Food Analogy
When supplements make statements of nutritional support, which are
exempt from drug regulation, it is important to look carefully at what
makes the ingredient a "dietary" ingredient. Clearly, statements of
nutritional support are not limited to the effects of nutrients since the
statements can be made both for nutrients and dietary ingredients. The
term "dietary" suggests, however, some analogy to food use and the
effects consumers expect from foods in the diet.' If this approach is
correct, claims that a dietary supplement provides a food-like energy
boost, provides a wake-up effect like coffee, soothes to sleep like warm
milk, or "promotes regularity" like fruits, would be appropriate. Such
food analogies are clear enough that consumers can understand the
context and types of effects to be expected. These claims are dietary in
the sense that the supplement is represented as a food substitute-as a
substitute source for the types of effects produced by ordinary foods in
the diet.
Claims that substances not found in foods achieve effects not usually
associated with foods should not be considered dietary claims merely
because the claims are not disease claims. If balsa wood were shredded
and put in a gelatin capsule, it would not be an appropriate statement of
nutritional support to say that the product is an "internal swim aid" to
help flotation. 33 To view such a claim as "dietary" expands the term
to cover the non-therapeutic effects of any biological substance
whenever the product is verbally described as having the effect of a

131. See ProposedRule, Dietary Supplements, 62 Fed. Reg. at 30,699; supra note 117.
132. See COMMISSION REPORT, supra note 16, at 38 (statement of the author that an
appropriate statement of nutritional support "would need to identify a dietary relationship for the
supplement").
133. See generallyTHOR HEYERDAHL, KoN-TII (1957) (discussing the buoyant nature of
balsa wood).
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dietary ingredient. While a claim as a swim aid would presumably be
precluded by the FDA's position that dietary claims have to relate to
health promotion, the need to have an analogy to a food use has a
separate focus."M Thus, claims that a substance from a tree improves
memory and enhances mental focus or prevents aging (or, for that
matter, improves intelligence or makes one think better) have no food
or diet parallels. 3 Claims that a supplement may be used as an oral
contraceptive similarly would be inappropriate. Contraception is not
itself a disease claim but it relates to the structure and function of the
body. It would be absurd to believe that Congress intended such a claim
to qualify as a "statement of nutritional support."
What constitutes a food- and diet-related use under this approach
depends primarily upon the claim. The test is claim-specific and relates
to whether a consumer would be able to understand how the supplement
is to be used to obtain effects normally associated with the use of foods.
The source of the supplement is a relevant but not a dispositive factor.
If the ingredient comes from a food source, the claims are more likely
to be understood by the consumer as diet-related.
This theory for limiting structure and function claims is not without
its difficulties. Using the term "dietary ingredient" to limit statements
of nutritional support could be seen as inconsistent with the broad
definitional scope of "dietary supplements" discussed above.'3 6 The
definitional section and the statements of nutritional support are
separate, however. Even if a statement of nutritional support cannot be
made, the substance can continue to be sold with simply the claim that
it is a dietary supplement, when it does not make disease or non-dietary
claims and there is no other basis for finding that the product is
intended to be a drug. Allowing sale when the only claim is as a dietary
supplement is consistent with congressional concern that consumers have
access to dietary supplements for dietary purposes even if these are not
recognized nutritional uses.
When a manufacturer makes a more specific claim about the dietary
effects of a supplement, different issues arise. The manufacturer who
promotes a supplement for a specific "dietary" use to the public-at-large
has a greater responsibility to make a claim that gives "dietary" an
understandable meaning. The requirement of substantiation for state-

134. See supra note 126 and accompanying text; discussion pt. III.C.2.b.
135. Claims of improved memory may also indirectly suggest a usefulness in treating the
effects of Alzheimer's Disease. There have been some short-term studies that have shown some
improvement in some patients, but the results are preliminary. See Transcript, World News
Tonight with Peter Jennings (ABC television broadcast, Feb. 6, 1997).
136. See discussion supra pt. III.B.2.
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ments of nutritional support indicates that Congress had greater concern
about the validity of these claims. In addition, Congress used the title
"statements of nutritional support" for claims concerning nutrients and
the need for some connection
"dietary" ingredients, thus indicating
37
diet.1
the
and
claim
the
between
At a minimum, statements of nutritional support for a dietary
supplement should expressly indicate that the supplement has a "dietary"
role. The label claims should specify that the supplement achieves its
effect through "dietary support," "dietary promotion," or in other terms
that expressly identify the role as a "dietary" one. An express dietary
reference serves to differentiate the effects of supplements from those
of drugs. The manufacturers who make the claims also should have the
burden of convincing the public that the role is a "dietary" one-a
burden that may be difficult for unfamiliar ingredients.
c. "Dietary" and Need for Professional Advice
Another meaning that can be inferred from the term "dietary" is that
claims should not refer to uses that require professional supervision and
a prescription.3 3 A drug can require a prescription because of its
toxicity or139because of the need for diagnosis to treat a more serious
condition.
Dietary ingredients, like foods, should be within the ability of a
consumer to use without medical supervision. As the Commission
recognized, a claim of effectiveness for prescription drug claims, such
as use as an oral contraceptive would be inappropriate for a "dietary
supplement," even assuming the supplement were effective for this
purpose."4
The principle that dietary supplements should not claim prescription
uses that need medical supervision represents an important aspect of the

137. The NLEA requires FDA approval for claims concerning disease and "health-related
conditions" for conventional foods and for dietary supplements that are nutritive. See 21 U.S.C.
§§ 343(r)(1), 343(r)(5)(D). When a nutritive supplement makes disease claims, the FDA may
possibly regard the claim as an unauthorized health claim rather than an unauthorized drug
claim. The NLEA also applies to claims about "health-related conditions." See id. This
independent requirement of the NLEA could impose limits on "structure or function claims" for
dietary supplements and conventional foods even when the claims are not sufficient to be disease
claims. In other words, the NLEA has a coverage that goes beyond disease claims and
encompasses abnormal health conditions that can lead to disease.
138. A drug is limited to prescription status when it is not safe for use except under
professional supervision because of "its toxicity, other the method of its use, or the collateral
measures necessary to its use." 21 U.S.C. § 353(b)(1)(B) (1994).
139. See United States v. 'Decholin', 264 F. Supp. 473, 479-80 (E.D. Mich. 1967).
140. See COMMISSION REPORT, supra note 16, at 37.
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boundary between dietary supplements and drug claims. The need for
a prescription helps both to indicate that a claim is a disease-related
claim and that a claim is not a dietary claim. The Commission also
recognized that nutritional support claims should not relate to matters
beyond the ability of the consumer to evaluate.'41
There may be debate with respect to some products whether
professional diagnosis and supervision is needed, and additional
attention will have to be given to the factors that necessitate prescription
limitations. 2 The principle is, though, an important one in establishing some discernible boundaries to protect consumers from inappropriate
claims.
3. Substantiation for Statements of Nutritional Support
Additionally, statements of nutritional support must be substantiated
4 3 This is an important requirement that may
and cannot be misleading.Y
preclude many claims. The FDA may directly challenge dietary
supplement claims that make express or implied disease claims as
inappropriate dietary supplement claims. For non-disease claims in a
gray area, the difficulties in litigating the issue of what is a "dietary"
claim may lead the agency to emphasize, as an enforcement priority,
whether there is adequate substantiation for the claim. The adequacy of
the substantiation for the claim may, in practice, be a more important
focus for enforcement and regulation than the difficult definitional
issues. Manufacturers may simply not be able to prove the vaguer
claims, and extensive and expensive research may be necessary for
claims that relate to preventative or moderate effects.'"

141. See id. at viii & 38-39.

142. See generally 'Decholin,' 264 F. Supp. at 473 (illustrating various factors necessitating
prescription limitations). In recent years, the prescription status of drugs has generally been
determined administratively-often without court litigation. See Hurr & MERRILL, supra note
29, at 416 n.2.
143. See 21 U.S.C. § 343(r)(6).
144. See COMMISSION REPORT, supra note 16, at 69 ("A statement that a product provides
a feeling of well-being may be confounded with the placebo effect, thus double-blind studies
using placebo would be essential to assessing such statements,"); see id. at 70 ("Determination

of prevention in the general population, or even in a population at risk for developing a specific
disease, is more expensive and difficult than determination of an effect in a population with a
disease."); see id. at 69-70 ("Many dietary supplements claim to improve or optimize the
functioning of the human body and do not result in immediate drug-like effects. The 'soft' end
points of research supporting such claims can make clinical research results ambiguous. The cost
of research to prove moderate benefits is significantly higher than that of research to prove
immediate relief of disease symptoms."); see id. at 69 ("A statement that a product enhances
immune function requires an appropriate challenge....").
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How demanding the substantiation requirement is depends, though,
upon the type of support needed to meet it. The Commission considered
the various factors that have been considered by the FTC in dealing with
the substantiation of advertising claims. The type of benefit claimed, the
difficulty of doing tests, and the amount of substantiation that experts
in the field consider reasonable affect the type of testing and support
necessary for general advertising claims.'45 For unqualified health
claims, the level of support among scientists that experts find necessary
is key."4 The Commission found that the "substantiation for statements of nutritional support will likewise vary depending on the nature
of the statement being made, the health importance of the statement, and
the difficulty of conducting experimental studies."' 47 These factors
suggest that significant agreement among scientists would be needed for
the statements of nutritional support that relate to conditions of health
importance, and that depend on difficult long-term testing.'48 For
significant scientific agreement to exist, scientists would need to know
about the information. Thus, the relevant studies and scientific information would need to be available to the scientific community, and, in
effect, be public. The public availability, when needed, also would help
alleviate the enforcement difficulties in determining whether the claims
have been adequately substantiated.

145. FTC Policy Statement on Advertising Substantiation, 48 Fed. Reg. 10,471 (1984),
reprinted in Thompson Medical Co., 104 F.T.C. 648, 839(1984), aff'd, Thompson Medical Co.
v. F.T.C., 791 E2d 189 (D.C. Cir. 1986), cert. denied, 479 U.S. 1086 (1987); FTC Enforcement
Policy Statement on FoodAdvertising, 59 Fed. Reg. 28,388,28,393 (1994). See generally C. Lee
Peeler & Susan Cohen, The Federal Trade Commission's Regulation of Advertising Claims for
Dietary Supplements, 50 FOOD & DRUG L.J. 349 (1995) (discussing the "application of the
Commission's regulatory approach to dietary supplements").
146. FTC Enforcement Policy Statement on Food Advertising, 59 Fed. Reg. at 28,393. The
FTC "regards the significant 'scientific agreement standard' . . . to be the principal guide" to
the support needed for advertisements about health claims on the relationship between food and
disease. Id.at 28,393.
147. COMMISSION REPORT, supra note 16, at 43.
148. The factors that influence scientists when there are difficulties in conducting tests is
also indicated in a report of the National Research Council (NRC) upon which the FDA relied
in developing its regulations on health claims. See Diet and Health: Implicationsfor Reducing
Chronic Disease Risk, Committee on Diet and Health, Food and Nutrition Board, Commission
on Life Sciences, National Research Council, at 23 (1989). The NRC Committee on Diet and
Health recognized that direct studies of the causal effect of a dietary substance on health and
chronic diseases is often not possible. See id. at 23. The committee looked to other types of
studies, and the "strength, consistency, and preponderance of data and the degree of concordance
in epidemiologic, clinical, and laboratory evidence" in determining the strength of the evidence
that supported the recommendations made by the panel with respect to health claims and food.
Id. at 38; see also COMMISSION REPORT, supra note 16, at 31.
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Some Commission members believed that historical use would be
recognized by experts as sufficient substantiation in the case of a
qualified claim that relied on historical use as support.'49 Another
assessment is that experts still would want scientific support for
substantiation in the case of claims that have health importance."5
DSHEA imposes an affirmative substantiation obligation for statements
of nutritional support, and not simply a disclosure obligation about any
inadequacies in the substantiation. Moreover, even if a claim is
qualified, there can still be the potential to mislead consumers unless a
qualified claim fully indicates the existence of any controversy among
experts, and any inconsistency of the claim with the larger body of
evidence.'
To make this substantiation obligation a meaningful one, the FDA
has to be able to obtain access to the files of the manufacturer to
determine whether the manufacturer has affirmatively developed support
for the claims made. The FDA, however, does not have the subpoena
powers that the FTC has. While the FDA can inspect the documentary
records of manufacturers of new drugs, the FDA has no express
authority to inspect the records of food or supplement manufacturers. Without that authority, it may be difficult to enforce the substantiation obligation with respect to labeling claims.' If the manufacturer relies on studies that are not public, there is an especially great
need for access to private files to ensure that there is substantiation.
While the FDA can take enforcement action if it can affirmatively show
that there has been a failure of substantiation, the need to make this type
of showing is difficult and essentially shifts away from the manufacturer
the need to develop adequate support. The FDA should test its authority
under the existing law to require manufacturers, by regulation, to make
records available when there is a need for access." If that regulatory
149. See COMMISSION REPORT, supra note 16, at ix-x & 43-44.

150. Id. (statement of individual member of the Commission).
151. See id.; FTC Enforcement Policy Statement on Food Advertising, 59 Fed. Reg. at
28,394.
152. See 21 U.S.C. § 374 (1994). With respect to the FTC's investigative powers, see 15
U.S.C. § 49 (1994); Antitrust Law Developments, A.B.A. ANTITRUST L. SEC. REP. ch. VH
(1997).
153. See BASS & YOUNG, supra note 56, at 57.
154. See Food Labeling; Nutrient Content Claims and Health Claims; Special Requirements, 61 Fed. Reg. 3885 (1996) (proposed rule to be codified at 21 C.F.R. pt. 101). The FDA
authority is disputed and rests on a theory raised in the 1960s but found not ripe for review apart
from a particular dispute. See, e.g., Toilet Goods Ass'n v. Gardner, 387 U.S. 167 (1967); see
also COMMISSION REPORT, supra note 16, at x & 44 (individual statement that the FDA should
have access to files to substantiate safety and statements of nutritional support through this type
of rule or through legislative action if necessary).
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authority is not recognized, Congress should provide adequate authority
by legislation.
D. Labeling Exemption for "Publications"
1. DSHEA Provisions
DSHEA created an important exemption, with uncertain bounds, for
a "publication" that is used "in connection with sale," even though the
publication may contain information about therapeutic uses of supplements.'55 An exempted "publication" is not considered "labeling"
subject to the requirements of the FFDCA.'" A book or other writing
that relates to the drug uses of a product only becomes subject to FDA
regulation when the written material "accompanies" a product or is used
as part of an integrated scheme to promote the product at the time of
sale.157 Labeling subject to the FFDCA cannot contain disease or other
drug claims without meeting the obligations for testing and pre-market
approval applicable to drugs.' By allowing manufacturers and sellers
of supplements to make available to consumers exempted "publications,"
DSHEA opens up the possibility of promotion of the supplement for use
by consumers for disease purposes that the manufacturer would not be
able to claim on the labeling itself.
Only certain publications are exempt, but determining the exact
scope of the exemption presents issues. The law refers to a "publication,
including an article, a chapter in a book, or an official abstract of a
peer-reviewed scientific publication that appears in an article and was
prepared by the author or the editors of the publication, which is
reprinted in its entirety.. . ."'" The sparse official legislative history
for DSHEA specifically states that the exemption "does not apply to a
summary of a publication other than an official abstract of a peerreviewed scientific publication."''
To qualify for the exemption, the publication cannot be misleading
and must be displayed or presented, or be displayed with such other
items on the same subject matter as to present a "balanced view" of the

155. See 21 U.S.C. § 343-2 (1994).
156. Id. No exemption is made in DSHEA with respect to the FrC's jurisdiction over
advertisements that are misleading. See 15 U.S.C. §§ 45, 52 & 55 (1994).
157. See discussion supra pt. II.A.
158. See 21 U.S.C. § 343-2.
159. Id.
160. See 140 CONG. REC. H1180 (daily ed. Oct. 6, 1994) (Statement of Agreement); 140
CONG. REC. S14,801 (daily ed. Oct. 7, 1994). The Statement specifies that it is "the entire
legislative history for DSHEA."
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available scientific information.' 6 ' The publication cannot promote a
particular manufacturer or brand, and the displays in a retail store have
to be physically separate from the supplements, and not contain
appended stickers.'62
2. Analysis
a. Scope of Exemption
The Commission report discussed the difficult issues in determining
the scope of the publication exemption. One possible interpretation
could be that the term "publication" is limited only to publications
directed to the scientific community, and not to consumer-directed
material. The Commission found that the emphasis in the statute on
reprinting a publication "in its entirety," "the care given to describing
an official abstract of a scientific publication," and the legislative history
on summaries "all suggest that Congress was referring primarily to
scientific publications."' 63 Nonetheless, the Commission recognized
that the term "publication" has a broader meaning, and would "appear"
to apply to almost any publication about scientific information.'" The
legislative history indicates that the exemption applies only to summaries that are official abstracts of articles, but scientific articles can be
review articles that contain summaries of various studies, and these
would also seem to be publications under this provision.
Another limitation clearly has merit. Specifically, an exempted
publication "should be independent and should not be written, developed, or funded by the manufacturers or sellers of dietary supplements."'65 Further, the writing of the publications should not be
financed by the sellers (apart from any support provided for the
underlying scientific research). The provision on abstracts clearly
reflects a concern with independence, and the references to book
chapters and articles is also consistent with having a distinct author. The

161. 21 U.S.C. § 343-2.
162. Id.
163. COMMISSION REPORT, supra note 16, at 46.
164. Id. at xi & 47. The provision still can be considered ambiguous because the statutory
reference to peer-reviewed scientific publications indicates the type of publication to which the
provision applies, and there would have been no reason to refer specifically to such publications
if the exemption was meant to be open-ended.
But see BASS & YOUNG, supra note 56, at 51-52 (expressing the view that the provision is
not limited to "third party literature," and that a publication can itself be a summary of the

literature).
165. COMMISSION REPORT, supra note 16, at 47 (stating the individual view of one of the

Commission members).
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provision that the publication be reprinted "in its entirety" makes sense
only if the publication is written by someone other than the one using
it in connection with sale, for the writer (or the one who employs or
who can control the writer) can always determine the content and length
of a writing. The term used in the industry to refer to the exempted
publications-"third-party literature"--supports reading the term as
referring to writings about scientific information produced by those not
involved in promotion of products. 166 A statutory change should be
considered if the term "publication" in DSHEA cannot be interpreted to
be limited to publications authored independently of the sellers of
products.
Some further examination of the scope of the exemption is also
appropriate in view of the treatment of "off-label" use claims permitted
for new drugs under a recent legislative change. That legislation for the
first time allows manufacturers of approved new drugs to distribute
unabridged information from scientific or medical journals, or reference
publications, about clinical investigations considered to be scientifically
sound by experts, when the manufacturer files a supplemental application with the FDA that provides for any additional research that may be
needed. 67 Ironically, dietary supplement manufacturers appear to have
a greater ability to use publications to promote sales to consumers about
"off-label" disease use. This is especially surprising because the
consumer purchases the supplement directly without consulting a
physician for a prescription, as ordinarily occurs with a new drug.
Consideration is needed concerning whether the publication
exemption for supplements should have limits similar to those applicable
to new drugs, including limiting the scope to the same type of scientific
publications, and providing for additional research testing. Supplement
manufacturers may believe that they should be able to use publications
to make claims with fewer restrictions and fewer testing requirements
than those that apply to pharmaceuticals because of the difficulties they
have had in patenting natural products and financing drug testing.
However, there should be a concern with protecting the consumer
interest and equitable treatment. To the extent research incentives are a

166. See id. (describing "third-party literature" as "the term often used within the industry"
to refer to exempt publications); compare BASS & YOUNG, supra note 56, at 51 (recognizing
that the exemption provision "often is referred to as sanctioning the use of 'third party
literature,' but stating there is "no restriction on who may author a 'publication' ").
167. See Pub. L. No. 105-115, § 401, 111 Stat. 2296, 2356-61 (1997) (to be codified at 21
U.S.C. §§ 551, 552 & 554). If the publication exemption in DSHEA cannot be interpreted to be
limited to scientific publications, a statutory change should be considered.
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factor, more study is needed of ways to provide these incentives, as
discussed below."
Limits also are needed on the use of publications in connection with
the sale of supplements when the publications promote uses, such as
treatment for depression, that require a prescription because of the need
for medical supervision. 69 Publications also should not be used to
promote claims that have been found to be inappropriate dietary claims
for use on the label. Thus, publications should not suggest recreational
drug uses for ephedra, or make medical claims for "herbal phen-fen"
substitutes or other claims that are not permissible dietary label claims.
A "publication" promoting such uses may fall to meet the requirement
that it not be misleading, but more consideration is needed of the
general
eligibility of publications to promote these types of non-dietary
70
uses.1

b. Ensuring a "Balanced View"
The Commission also recognized the particular difficulties in
ensuring that publications give a "balanced view" of the available
scientific information. Scientific articles reporting on research or
reviewing the literature generally are well-balanced, but these articles
are not likely to be "consumer friendly."'' In practice, most publications presently used under this provision of DSHEA are specially
prepared and are directed to consumers. The Commission report
described the balanced view requirement as involving "a need to
acknowledge negative as well as positive data and to indicate which

168. See discussion infra pt. V.B.3. The new law applicable to pharmaceuticals authorizes
the FDA to make exemptions from the provisions on additional testing in limited cases in light
of factors such as lack of exclusivity and limited size of patient population. See § 401, 111 Stat.
at 2359-61 (to be codified at 21 U.S.C. § 554). The legislative history indicates this exception
is to be limited. Joint Explanatory Statement of the Committee of Conference, 143 CONG. REC.
H10475, H10477 (daily ed. Nov. 9, 1997). Similar factors should be considered for supplements
for which manufacturers are obliged to do additional testing in connection with new uses
promoted in publications.
169. The need to prevent deception may limit the use of publications for prescription drug
uses. See 21 U.S.C. § 343-2(a)(1). To avoid being misleading, the publication would need to
warn consumers not to use the product without medical supervision, but the use by the seller of
the publication to promote over-the-counter sale to consumers could be seen as undercutting the
warning in a way that is deceptive.
170. If the use is a prescription use, the use of a publication to promote that use can be
misleading. Id. If the name or potent effects of the product indicate that it is to be used for drug
purposes, the exemption would not be applicable since it relates to use "in connection with the
sale of a dietary supplement." 21 U.S.C. § 343-2 (emphasis added); see discussion supra pt.
III.B.2.
171. COMMISSION REPORT, supra note 16, at xi & 46.
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position is supported by the weight of the evidence."'1 2 The Commission did not develop a set of guidelines on what constituted balance, but
it recommended that the FDA undertake
"proactive monitoring" and
73
provide regulatory guidance as needed.
Some believe that a particular publication need not be balanced so
long as it is displayed with other publications to provide an overall
balanced view. 7 DSHEA provides two ways to provide a balanced
view: either by display or presentation, or by display or presentation
"with such other items on the same subject matter" so as to present a
"balanced view."' 75 There are "particular difficulties" in trying to
provide a balanced view by displaying positive with negative publications, and some Commission members recognized that further study is
needed to determine whether there are adequate
and reliable means to
1 76
ensure a balanced view in such a setting.
One difficulty is that the display of material to counter unbalanced
material would probably be made at the retail level, but the economic
interest of retailers can cut against providing the material on a consistent
and reliable basis. If one accepts that a particular publication can be
unbalanced, perhaps what is needed is a regulatory requirement that an
unbalanced publication prominently state on its cover that it is unbalanced and that consumers need to consult specified other publications
to obtain an overall balanced view.
DSHEA precludes false and misleading statements in provisions
separate from the balanced view requirement. 77 Congress may have
had a special concern with the need for balance as a way to prevent
deception because of the difficulty consumers have in evaluating
complex scientific information about a product that can affect their
health. This interconnection between the means to prevent deception and
the need for a balanced view provides support for the congressional
ability78 to impose such a requirement consistent with the Constitu1
tion.

172. See id. at 46.
173. Id. at xi & 48.
174. See BASS & YOUNG, supra note 56, at 51-52 (presenting the view that, while a
balanced view is necessary, that can be presented within a single publication; however, display
with other material is needed when the publication itself is unbalanced).
175. 21 U.S.C. § 343-2(a)(3) (1994).
176. See COMMISSION REPORT, supra note 16, at 47.
177. See 21 U.S.C. § 343-2.

178. The Supreme Court has recognized that the First Amendment does not protect
commercial speech that is misleading. See Central Hudson Gas & Elec. Co. v. Public Ser.
Comm'n, 447 U.S. 557 (1980); see also Nutritional Health Alliance v. Shalala, 953 R Supp. 526
(S.D.N.Y. 1997) (addressing constitutionality of requirement for regulations on health claims).
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E. Safety of Dietary Supplements
1. DSHEA Exemption from the Food
Additive Requirements
DSHEA exempts dietary supplements from being considered food
additives.'79 Ordinarily, any substance added to food that is not
generally recognized as safe requires approval by the FDA in advance
of being sold. 8° In the past, the applicability of the food additive premarket approval requirement was a means of limiting the sale of some
supplements, even apart from the restrictions imposed by the drug
efficacy requirements.'

The food additive provisions made it much easier, in theory, for the
FDA to ensure the safety of the supplements. The FDA did not have to
prove the lack of safety of an additive-only that the safety was
generally unknown to experts. On the other hand, the FDA did not
always seek to enforce these food additive requirements rigorously, and
acted primarily when specific problems had been identified. When
the FDA stated its intent to apply the requirements to amino acids in the
FDA Advance Notice,' the prospect of the removal of the products
from sale helped lead to the enactment of DSHEA."'
Court decisions had narrowed the applicability of the food additive
provisions to supplements even before the enactment of DSHEA. When
a product consists solely of a "single active ingredient" packaged in an
inert gelatin capsule, the courts have refused to view the combination as
falling within the definition on the basis that there has been no effect on
the characteristics of a food, or no addition of a substance to a food.'85
The scope of Congress' ability to regulate speech that is truthful in order to promote a public
purpose is much debated and beyond the scope of this Article. See, e.g., 44 Liquormart v. Rhode
Island, 517 U.S. 484 (1996).
179. See 21 U.S.C. § 321(s)(6).
180. See 21 U.S.C. § 321(s); 21 U.S.C. § 348 (1994).
181. See Stephen H. McNamara, FDA Regulation of Ingredients in Dietary Supplements
After Passage of the Dietary Supplement Health and Education Act of 1994: An Update, 51
FOOD & DRUG L.J. 313, 315 (1996) (reporting that, before DSHEA, FDA "allegations" of food
additive status "had resulted in the end or curtailment of marketing for many products").
182. See discussion supra pt. II.C.
183. See supra note 58.
184. See discussion supra pt. II.D.; Kassel, supra note 48, at 269 (reviewing safety issues
and concluding before the enactment of DSHEA that the "present climate of public opinion
seems to favor unlimited distribution of dietary supplements, but a supplement-related health
disaster could push the public opinion pendulum in a very different direction").
185. See, e.g., United States v. Oakmont Inv. Co., 987 F.2d 33 (1st Cir. 1993); United
States v. Viponte Ltd. Black Currant Oil, 984 F.2d 814 (7th Cir. 1993). The latter court noted
the relevance of consumer choice: the labeling requirements of the law protected consumers,
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2. Safety Provisions of DSHEA
In the place of the food additive provisions, DSHEA gives the FDA
the authority to bring court actions with respect to supplements sold
before the enactment of DSHEA when the product poses a "significant
or unreasonable risk" of injury under the conditions recommended or
suggested in the labeling. 86 This court enforcement approach is similar
to that used at the beginning of the century."8 7
For new ingredients in supplements not in use before 1994, the
manufacturer has the burden of affirmatively substantiating the safety of
the ingredient based on historical use or scientific information. 8' The
manufacturers must notify the FDA of the basis for the information that
is the basis for the determination that the product is reasonably expected
to be safe.'89
3. Analysis
The substantiation -model used by DSHEA for new ingredients
provides an intermediate approach between pre-market review and a
reactive court enforcement model. There are, however, difficulties with
respect to the scope of the substantiation obligation and the adequacy of
the FDA's resources and authority to enforce the provisions.
For "grandfathered" pre-1994 supplements, the FDA has the burden
to affirmatively prove the existence of a significant or unreasonable risk,
a showing that is particularly resource-intensive." 9° Moreover, the
absence of a substantiation obligation sends the wrong message to
irresponsible manufacturers-namely, that they can sell a questionable
product until the FDA "catches" them. Instead, the manufacturer should
be affirmatively responsible to ensure that the product is safe.
The substantiation obligation should extend to all supplements, and
especially to those that contain a new statement of nutritional support
or other new claim, or that recommend any increase in dosage or
exposure that can increase safety risks. As long recognized, the safety

"enabling persons to weigh for themselves the benefits and risks of consuming [Black Currant
Oil]." 984 F.2d at 820.
186. See 21 U.S.C. § 342(0.
187. See, e.g., United States v. Lexington Mill & Elev. Co., 232 U.S. 399 (1914).
188. See 21 U.S.C. § 350b (1994). The statute refers to a specific date, Oct. 15, 1994. For
convenience, this Article refers simply to the year.
189. See 21 U.S.C. § 350b. The FDA has issued rules to govern the matters to be included
in the notification letter. See PremarketNotificationfor a New Dietary Ingredient, 62 Fed. Reg.
49,886 (1997) (to be codified at 21 C.RR. 190.6).
190. See COMMISSION REPORT, supra note 16, at 22.
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of a product depends upon the dose. 9 ' Changes in the recommended
uses can affect the safety of the product, and such changes need careful
evaluation by the manufacturer. When a change is one that experts
would view as affecting the safety of the product, the manufacturer
should undertake testing or other evaluation that experts would find
necessary to ensure that the product is safe. A history of marketing
before 1994 does not necessarily provide assurance that the product met
the rigors of the food additive provisions, given the judicial narrowing
of the FDA's food additive authority and the limited FDA enforcement
of the provision.
The FDA can take some steps under the present law to make
manufacturers of supplements more responsible for determining the
safety of older supplements. The FDA could require supplements whose
safety has not been substantiated to bear a warning that the safety has
not been determined-a requirement that the FDA has imposed on
cosmetics to prevent consumer deception."92 The warning requirement
would not directly require substantiation, but the need for a warning
would be a significant inducement to manufacturers to provide it and
would prevent consumers from being misled that the product has been
tested.'93
Another approach would examine the scope of DSHEA's grandfather
provisions as it applies to increases in the dose above the level the
ingredient may have had in the food supply before 1994. DSHEA is a
deeply-compromised statute, and on this matter, as on others, its
provisions pull in different directions. DSHEA precludes new ingredients without substantiation unless they are ingredients "present in the
food supply as an article used for food" in a chemically unaltered form,
a test that might seem to require substantiation of old ingredients used
at higher levels or new uses that go beyond food uses. 4 On the other
hand, DSHEA defines a new ingredient as not including "any dietary
that
ingredient which was marketed" before 1994, a provision indicating
195
"new."'
supplement
a
make
not
do
levels
changes in dose

191. See Lexington Mill, 232 U.S. at 411-12.
192. See 21 C.F.R. 740.10 (1997). Cf Peeler & Cohn, supra note 145, at 354 ("[A]n
unsubstantiated claim of safety or a failure to disclose any significant or unreasonable risk...
could constitute a violation of the FTC Act.").
193. See COMMISSION REPORT, supra note 16, at 25 (statement of individual member of
the Commission).
194. 21 U.S.C. § 350b(a)(1). The FDA's procedures for notification for new ingredients call
for information on the level of use. See Premarket Notificationfor a New Dietary Ingredient,
62 Fed. Reg. 49,886 (1997) (to be codified at 21 C.FR. 190.6).
195. 21 U.S.C. § 350b(c); COMMISSION REPORT, supra note 16, at 20 (stating the view that
changes in dose do not make a supplement new).
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Arguably, one way to reconcile these provisions might be to view the
new ingredient category as including any ingredient that is used at levels
significantly higher than those in common use in 1994 for either food
or dietary supplement purposes. Such a reading would reach changes in
the level of use that could affect safety, but not require a notification to
the FDA of minor changes that experts would not view as cause for
concern. Reading the provision to encompass this type of change in the
level of use provides a better assurance of safety, but whether the text
permits the reading is open to debate.
The FDA also should identify the type of testing and scientific
support needed to substantiate the safety of supplements. Since the
safety of supplements is important to health, consideration has to be
given to the need for significant scientific agreement to adequately
substantiate safety. Ensuring that there is significant scientific support
for the safety of supplements needs to be considered for legislative
action if the present law does not provide sufficient authority.
Obtaining that level of support involves making the tests available
to the scientific community. Manufacturers, however, may resist a
requirement that would necessitate making publicly available tests or
support developed by them that they regard as confidential business
information vulnerable to use by their competitors. An examination is
needed concerning whether a process of independent expert review,
combined with provision of the full information to the FDA, and a
summary for the scientific community, would be viewed as sufficiently
reliable indicator of scientific agreement to provide substantiation when
clear testing criteria exist to determine safety.
F. Resources and Enforcement Modelfor Regulation
The FDA's ability to enforce the manufacturer's obligation to meet
any substantiation obligation effectively (including the obligation of the
manufacturer to substantiate statements of nutritional support) is not
clear."9 The FDA does not have the express authority to inspect the
documentary records of food and supplement manufacturers. The FDA
has proposed regulations that would require manufacturers to provide
access to files needed to determine whether certain requirements relating
to nutrient content and health claims on foods have been met.1" The
FDA's authority to impose these types of requirements is debatable and
has not been tested. If the FDA does not have that authority under the
existing law, Congress should enact legislation to require all supplement
196. See discussion supra pt. III.C.3.
197. See 61 Fed. Reg. at 3885 (1996); COMMISSION REPORT, supra note 16, at 26
(statement of individual member of the Commission).
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manufacturers to substantiate the safety of their products, and to give the
FDA the power to inspect substantiation files.
The adoption of a court enforcement and substantiation model,
instead of a pre-market approval model, to determine the safety of
supplements has an important impact on the ability to enforce the law.
When pre-market approval is required, but the agency does not act
promptly on requests for approval, the product is not sold to consumers
and delay has an adverse impact on industry applicants. The industry,
thus, has a stake in ensuring that the agency has the personnel and
resources to meet its statutory. review responsibilities. As a result, the
drug industry has supported the imposition of user fees for new drug
applicants as a way of providing the FDA with more resources, and the
FDA has acted faster on applications.19 When the agency can only
take enforcement action in court, the less responsible members of the
industry do not have the same concern with being sure that the agency
can bring enforcement action when needed.
The Commission recognized the need for the FDA to have adequate
resources to enforce the safety requirements of DSHEA in order to
protect the public and to maintain public confidence in the safety of the
products as a whole.1 Indeed, the FDA has been urged to act faster
to bring enforcement action to deal with the safety problems raised by
the sale of ephedra-containing products, such as herbal ecstasy, which
have caused deaths and other injuries at high levels.2' In this era when
balancing the budget is a high governmental priority, it can be difficult
to obtain additional resources for enforcement measures, however. More
study is needed of ways to ensure adequate resources when Congress
has adopted an enforcement/substantiation model relating to health
regulation.
G. Summary
Overall, DSHEA provides an expanded opportunity for dietary
supplements-particularly the non-nutritive ones-to make structure and
function claims without being subject to drug regulation. Uncertainties
remain, however, about the appropriate scope of these claims and the
type of substantiation needed. What limits are ultimately established will
affect how readily manufacturers can make claims that indicate, in some
indirect way, the usefulness herbal and other supplements may have in
198. See 21 U.S.C. § 379h (as amended by § 103, 111 Stat. at 2299-2304) (regarding user

fees for prescription drugs)).
199. See COMMISSION REPORT, supra note 16, at vii & 26.
200. See id. at vii & 22. The FDA has proposed rules to limit the use of ephedrine alkaloids

in dietary supplements. 62 Fed. Reg. 30,678 (1997); see discussion supra pt. III.C.2.b.i.
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preventing and treating diseases. The publication exemption also creates
an opportunity for sellers of supplements to provide scientific information about the uses of supplements for disease purposes. The bounds of
this exemption and its limitations are not fully determined.
The FDA needs to provide guidance concerning the appropriate
scope of these new provisions, to take steps to limit inappropriate
claims, and to test its authority to obtain access to the supporting
records when needed. The FDA needs, as well, to consider requiring a
warning on supplements marketed before DSHEA that have failed to
substantiate their safety. Such a requirement would at least legally
oblige manufacturers of all supplements to take affirmative steps to
determine the safety of their products, a measure that is especially
necessary when dosage levels significantly increase.
IV. THERAPEUTIC CLAIMS FOR SUPPLEMENTS THAT MEET THE DRUG
EFFICACY REQUIREMENTS: THE ROLE OF THE OTC REvIEW
Even with the expansions in DSHEA, dietary supplements cannot be
offered with claims on the labeling that clearly relate to use in treating
or preventing disease unless they meet the legal requirements for testing
and FDA approval or general recognition. Before considering whether
there should be an alternative system for disease claims on supplements,
it is important to understand the existing legal requirements governing
drug claims and to recognize that some supplements may be able to
meet the present requirements. These matters are considered below,
along with the recommendations of the Commission to facilitate FDA
review of OTC drug claims for botanical supplements.
A. New DrugApplications
Any "new drug" needs pre-market approval by the FDA, based on
a new drug application (NDA), that shows the product is safe and
effective through adequate and well-controlled studies.2"' Obtaining
approval of an NDA is a time-consuming and costly endeavor.
In the past, the FDA required that the active ingredients of a new
drug be fully identified to determine their contribution to efficacy.
Herbal products could not ordinarily meet this requirement because of
the complex nature of natural products. The FDA no longer requires this
full characterization of natural products so long as adequate
compositional data are submitted. Additionally, the FDA has accepted
a few investigational new drug applications (IND) for natural prod-

201. See 21 U.S.C. § 355.
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ucts. °2 Clinical testing is also underway on an expedited basis for
claims relating to certain botanical products. 3
Conceivably, manufacturers of herbal products or other supplements
could seek approval of an NDA. New drugs are typically sold as
prescription drugs initially. Manufacturers of supplements are likely to
prefer the other means the FDA uses to recognize the appropriateness
of selling a product as a drug, through OTC review.
B. OTC Review for Generally Recognized Drugs
1. History
Drugs can be marketed without FDA approval of an individual
approval of an NDA for a particular drug if the drug is "generally
recognized as safe and effective" (GRASE). °4 That recognition, by
definition, makes the product no longer a "new drug," removing the
need for an individual approval of an NDA. To be generally recognized,
however, products ordinarily must have the same type of tests needed
to obtain approval of an NDA and must have been used for a material
time and extent.' 5 Thus, qualifying as GRAS/E involves an additional
element-that of showing general recognition.
The FDA has recognized a large number of products as being
GRAS/E, notably the ingredients in many drugs sold over-the-counter.
Many of these products had been sold long before the drug efficacy
testing requirements were adopted in 1962. The FDA convened advisory
committees that reviewed the testing for the OTC drugs. The panels
identified the ingredients and uses for which adequate support and
general recognition existed, those that were ineffective, and those for
which further testing was needed. In a rulemaking proceeding dealing
with the ingredients on a generic basis, the FDA recognized some
ingredients and uses as GRAS/E, and some not, taking account of the

202. See Nigel Gericke, The Regulation and Control of Traditional Herbal Medicines,
Traditional Medicines Programme, University of Cape Town, South Africa, at 16 (1995)
(unpublished draft, citing statement of Dr. Robert Temple, Director, FDA Office of Drug
Research and Evaluation, at the Office of Alternative Medicine Conference on the Role of
Botanical in American Health Care, Dec. 1994) (on file with author).
203. See, e.g., Pharmaprint'sSaw Palmetto-DerivedDrug in Phase llfor Benign Prostatic
Hypertrophy, THE TAN SHEET, Oct. 6, 1997 (reporting tests for claims for benign prostate
hypertrophy and for St. John's wort and depression).
204. 21 U.S.C. § 321(g). There also are certain drugs which have been grandfathered from
the new drug requirements, but this grandfather status is narrow and is lost if the claims for the
product are changed. See, e.g., USV Pharmaceutical Corp. v. Weinberger, 412 U.S. 655 (1973);
United States v. Allan Drug Corp., 357 F2d 713 (10th Cir.), cert. denied, 385 U.S. 899 (1966).
205. See Weinberger v. Hynson, Westcott & Duning, 412 U.S. 609, 631-32 (1973).
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advisory committees' recommendations.' This OTC review, which
started in 1972, has completed its major work, although the final rules
on some minor ingredients remain to be issued. A few herbs were
recognized as effective in the OTC review °7
2. Botanical Advisory Review Panel
The Commission has recommended that the FDA convene an OTC
advisory panel for botanical products to review submissions for herbal
products that can show general recognition of safety and efficacy for
sale as OTC drugs.0 8 The current interest of the public in herbs makes
it appropriate for the FDA to give serious renewed consideration to
these products. Manufacturers of many herbal products may seek to
make claims for uses long recognized as OTC uses by the FDA, such
as use as a sleep aid, or for treatment of cold symptoms.
The botanical products considered in such a review should meet the
requirements of the existing law. The FDA's regulations for OTC drugs
require adequate and well-controlled tests. Traditional use and anecdotal
evidence is insufficient.' There has, however, been some debate
about the rigor with which the criteria were applied in the past.
The FDA regulations recognize that there can be waivers of
requirements for controlled testing which are not reasonably applicable
or essential to the validity of the study, and where alternative methods
of investigation are available." 0 There have been few express waivers,
and in one case the condition involved "mechanical action" and
professional examination.' A Supreme Court decision involving OTC
drugs recognized that the FDA may have some measure of discretion in
applying the GRAS/E standard.212 The Court stated that "in some cases
general recognition" may be achieved without the kind of testing needed

206. See generally 21 C.ER. 330.10 (procedures for classifying OTC drugs as GRASE and
not misbranded); 21 C.F.R. pts. 330 to 358 (rules on specific OTC categories); Cutler v.
Kennedy, 475 F. Supp. 838 (D.D.C. 1979) (discussing the process and legal standards, and
rejection of recognition in the final rules of products needing further testing).
207. See COMMISSION REPORT, supra note 16, at 54, 55 (for example, elm bark as an oral
demulcent).

208. See id. at xii & 57.
209. See 21 C.FR. 330.10 (1997). Adequate tests can be of different types: placebo
concurrent control, dose-comparison concurrent control, no treatment concurrent control, active
treatment concurrent control, and historical control. 21 C.F.R. 314.26 (1997).
210. 21 C.F.R. 330.10(4)(ii).
211. See COMMISSION REPORT, supra note 16, at 55 (citing Topical Otic Drug Productsfor
Over-the-Counter Human Use: Tentative Final Monograph, 47 Fed. Reg. 30,012, 30,013
(1982)).
212. See Weinberger v. Bentex Pharmaceuticals, Inc., 412 U.S. 645 (1973).
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to obtain approval for an NDA, 213"[b]ut... the reach of scientific
inquiry... is precisely the same.
The Commission recommended that the type of testing done for
existing OTC products for a certain use be considered the benchmark in
determining what is acceptable testing for herbal products for the same
use.2" That comparability in the level of testing would ensure a level
playing field. The botanical products should not be subject to lower
testing standards than those that apply to conventional OTC products for
the same use, but correspondingly, they should not be subject to higher
standards. If more testing is to be required, the FDA should have to
justify the result in terms of how it serves the interest of consumers who
would be using the products for the same purposes.
The FDA recently has invited comments on a policy under which it
would consider foreign data in the OTC review, but only with a
considerable showing that the foreign studies are reliable and applicable
to the United States population. 25 Detailed information would be
needed on adverse reaction reporting and the extent of marketing, which
may be difficult to obtain.21 6
V. STUDY OF ALTERNATIVE SYSTEM FOR THERAPEUTIC
CLAIMS FOR HERBAL REMEDIES: CHOICES ON THE
RATIONALE AND IMPLICATIONS

While there is a clear possibility that some herbal products may have
sufficient testing and recognition to meet the standards for approval
under the OTC review, there will be others that will not have the type
of scientific testing that is required. The Commission recommended that
there be more study of the alternative systems used overseas, and
identified some of the important issues that would have to be addressed
in such a study.217 Any study of an alternative to the existing requirements raises the possibility of a recommendation for a lesser standard
of efficacy than that required in the United States. Thus, the study, if
undertaken, would deal with a major public policy issue. The discussion
below is a reflection on the matters that would need to be considered if
a full study were to be undertaken.

213. Id. at 653-54 (citing Hynson, 412 U.S. at 631).
214. See COMMISSION REPORT, supra note 16, at 56.
215. See Advance Notice of Proposed Rulemaking; Eligibility Criteriafor Considering
Additional Conditions in the Over-the-CounterMonograph System; Requestfor Information and
Comments, 61 Fed. Reg. 51,625 (1996).
216. See id.
217. See COMMISSION REPORT, supra note 16, at xi-xii, 52 & 57.
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A. Traditional Use as a Rationalefor an Alternative System
1. Support for Changing the Standard
a. International Harmonization
With the globalization of trade there is increasing interest in the
extent to which there should be harmonization in the standards of the
industrialized countries governing pharmaceuticals." The establishment of the European Community also has led to a process through
which the community members work toward a compatible system of
drug regulations for prescription drugs and other products.2"9
The rationale for an alternative model for regulating botanical
remedies has an analogy in the efforts at harmonizing the regulation of
pharmaceuticals. However, it presents a new factor: the need to consider
the relevance of traditional use as part of the criteria for determining
efficacy. Only preliminary information is available about the criteria
used by other countries and a full understanding of the systems used in
herbal remedies in other countries would take a major
regulating
220
study.

The limited information available indicates that twelve of eighteen
industrialized countries have specific mechanisms allowing therapeutic
claims for herbal remedies based on a combination of historical and
scientific information.21 In some countries, clinical evidence is
required to support a recommended use, while in others traditional use
is sufficient for a limited therapeutic claim. Sometimes, disclaimers may
be required.2" In Germany, herbal medicines can be approved, based
on a review by an independent Commission called "Commission E,"
218. See Elizabeth C. Price, Teaching the Elephant to Dance: Privatizing the FDA Review
Process,51 FOOD & DRUG L.J. 651, 667-672 (1996); Joseph C. Contrera, Comment, The Food
and DrugAdministrationand the InternationalConference on Harmonization:How Harmonious
Will International PharmaceuticalRegulations Become?, 8 ADMIN. L.J. 927 (1995). Recent
legislation has encouraged the FDA to proceed with efforts at harmonization when it continues
consumer protections consistent with the purposes of American and to "move toward ... mutual
recognition agreements... [with the] European Union." 21 U.S.C. § 383(c) (as amended by §
410, 111 Stat. at 2372-73; see infra text accompanying notes 236-38.
219. See Richard F Kingham et al., The New European Medicines Agency, 49 FOOD &
DRUG L.J. 301, 301-03 (1994).
220. For additional commentary, see Edgar R. Cataxinos, Note, Regulation of Herbal
Medications in the United States: Germany Provides a Modelfor Reform, 1995 UTAH L. REV.
561; Scott Martin, Unlabelled "Drugs" as U.S. Health Policy: The Casefor Allowing Health
Claims on MedicinalHerb Labels; Canada Providesa Model for Reform, 9 ARIZ. J. INT'L &
COMP. L. 545 (1992).
221. See COMMISSION REPORT, supra note 16, at 52.
222. Id. at 52-53.
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funded by the government, whose members are nominated by professional societies and pharmaceutical companies.2' The criteria allow
approval for herbal medicines in the absence of controlled clinical trials,
based on standard literature and review articles, supplementary
experimental studies, or "well documented knowledge on traditional use
which is supported by significant experimental studies."2 " Apparently,
it is also possible in Germany to sell other traditional herbal products
that would not meet the criteria for approval by Commission E. These
remedies cannot be sold in pharmacies and must be sold with a
disclaimer that limits use to that of a tonic, "to support organ functions,"
or "as a mildly active drug."' Herbal remedies are widely used in
Germany and reimbursed by health care plans, and the herbal product,
St. John's wort, is reported to be more widely used for depression than
prescription drugs such as Prozac. 6
Other Western European countries have their own disclaimers. In
Ireland, for example, herbal remedies must bear the following labeling:
"Traditional herbal remedy for short-term treatment of slight discomforts
and that should be [sic] not be used for extended periods without the
advice of a physician. '
b. Research Costs
The difficulties in financing research on generic natural products can
be seen as a reason not to insist on controlled studies. The industry has
found that the difficulties in obtaining adequate patent protection
discourages research that would benefit competitors as well as the
companies that finance the research.22 The "gold standard" of controlled scientific testing can be seen as too demanding for natural
products when they cannot obtain protection for research that the patent
system makes possible for drugs synthesized and developed by
pharmaceutical companies.
c. "Better Than" the Present
Allowing direct claims regarding the therapeutic benefits of herbal
remedies can be thought better than the indirect ways that therapeutic
223. See Gericke, supra note 202, at 31.

224. Id.
225. Id. at 33-34.
226. Morning Edition (NPR News broadcast, Oct. 3, 1997) (transcript available by calling
1-888-NPR-NEWS).
227. Gericke, supra note 202, at 54.
228. See COMMISSION REPORT, supra note 16, at 69 (reporting public testimony to the

Commission).
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uses currently are suggested for these products. According to the
Commission report, "many botanicals now are being labeled with
statements of nutritional support that suggest only indirectly the type of
therapeutic use that is traditional for the product. In such cases, the
Commission questions whether the statement of nutritional support is
'
adequate to convey to consumers the intended use of the product."229
According to the Commission report:
The scientists on the Commission noted that in some cases,
current scientific evidence supports such uses. Most
Commissioners concluded that consumers would be better
served by clear information regarding such uses than by the
limited statements of nutritional support permitted by
DSHEA. Current efforts to use statements of nutritional
support to suggest such uses without overtly stating them
may not provide sufficient information to consumers and
may also create a climate of deception that serves neither
the industry nor consumers.'
As an illustration, the Commission cited statements of nutritional
support in regard to the effects of Echinaceae purpureae.23 The
statements of nutritional support on this supplement included the claim
that it "[n]utritionally supports healthy immune function."" In contrast, the World Health Organization (WHO) draft model monographs
for Echinaceae state that it is administered as an "immunostimulant, in
supportive therapy for colds and infections of the respiratory and urinary
tract," and that it "would ordinarily be administered together with other
antibacterial agents, such as antibiotics or sulfa drugs."233
2. Difficulties with Changing the Standard
a. The Placebo Effect and the Need for Studies
While the rationale for finding a product effective without clinical
testing based on traditional use may have some appeal, the position also
presents serious difficulties. For instance, the placebo effect is a reality,
and testing against a placebo is the best way to determine whether
improvement is due to the drug or, rather, some other factor such as
hope for improvement, the self-limiting nature of the underlying
229.
230.
231.
232.
233.

Id. at 48.
Id. at 56-57.
See id. at 50.
Id.
Id.
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condition, or another drug administered with the remedy." These
other factors bear on the effectiveness of herbal remedies as well as on
the effectiveness of other products. There surely are some traditional
remedies that may "cure" a cold, given enough time. Review by an
expert panel can provide some additional measure of reliability.
However, the judgment of experts is not fully reliable without adequate
testing.235 Without such testing, the criteria used by experts would rest
largely on their judgment. Who the experts are and how they are
appointed would become critical factors. 6
Ineffective drugs do not merely pose an economic cost. The drugs
can divert users from more effective therapy, and indirectly cause harm.
There also are human costs in lost hopes and time.
b. The Role of International Models
There has been a long debate about whether the United States drug
efficacy standards are inappropriate because they delay domestic use of
drugs approved overseas. 7 The increased globalization of trade has
led to growing interest in harmonizing United States standards with
those of other industrialized counties-particularly the standards of the
European Union. 8 Congress has encouraged harmonization with other
countries if harmonization "continues consumer protections consistent
with the purposes" of the U.S. laws, and also has supported efforts to
"move toward the acceptance of mutual recognition agreements" with
the European Union.23 9 While the harmonization of standards can
benefit trade and patients in the form of speedier drug approvals and the

234. The effects attributed to Echineae in the WHO monograph might, for example, be due
to the antibiotics or sulfa drugs used in connection with the botanical. See id.
235. See Hynson, 412 U.S. at 629-30. The Hynson Court interpreted the drug efficacy
amendments as requiring that general recognition by experts be based on adequate studies. See

id. at 631-32.
236. The OTC review uses expert panels and provides for waivers. However, these
judgments occur within a framework where controlled testing is the norm. This reduces the risk
of having the determination turn on purely subjective assessments. See discussion supra pt. IV.B.
237. See Price, supra note 218, at 665 (reviewing information on rate of approvals);
Michael J. Malinowski, Globalization of Biotechnology and the Public Health Challenges
Accompanying It, 60 ALB. L. REV. 119 (1996); Note, FDA Reform and the EuropeanMedicines
Evaluation Agency, 108 HARV. L. REV. 2009 (1995).
238. See Merrill, supra note 60, at 1863 (observing that FDA officials have been "deeply
concerned" about suggestions for international reciprocity that may involve "relinquish[ing]
decisional responsibility to bodies that devote many fewer resources and less effort to confirming
manufacturer claims that their products are safe and effective, even though such suggestions are
less threatening than private third party reviews").
239. 21 U.S.C. § 383(c) (as added by § 410, 111 Stat. at 2373); see Merrill, supra note 60,
at 1862-63.
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elimination of duplicative testing, it is also important that the legal
standards for drug approval not be lowered inappropriately and
unwittingly.2' To the extent that the international standards for herbal
products are equivalent to the American standards, the OTC review
provides a forum for examining the support for a particular remedy and
providing recognition if the standards are met. Efforts to give mutual
recognition to the standards of other countries for botanical remedies
raises a fundamental difficulty to the extent that the standards make
traditional use sufficient to establish efficacy without adequate scientific
testing.
c. Research Incentives and Equity
The difficulty in developing research incentives for generic products
does not justify dispensing with adequate testing for products that claim
to be effective. The problem is broader than herbal remedies.24 '
Manufacturers of herbal remedies also would receive a substantial
competitive advantage over other pharmaceutical manufacturers if they
could make drug claims without having to undertake the research and
testing that contributes so substantially to the high cost of drugs. Herbal
remedies would gain the benefit of an uneven playing field in comparison with proven drugs.
The better course would be to provide research incentives to
manufacturers of herbal products who perform testing that protects them
against free riders. There are limited non-patent protections under the
laws governing drugs for manufacturers of products that obtain drug
approvals based on new clinical research.242 More study should be
given to ways to develop research incentives for botanical products if
additional measures are needed. Perhaps those who rely on the testing
done by others should have to either share the costs or pay royalties.
Perhaps there should be some type of exclusivity for such claims. For
generic agricultural products, there are "checkoffs" for commodities
used to finance research that benefits the industry at large.243 Government research funding may be appropriate for long-term studies of

240. See Gilhooley, supra note 92.
241. See THE KEYSTONE CENTER, THE KEYSTONE NATIONAL POLICY DIALOGUE ON FOOD,

NUTRITION, AND HEALTH, FINAL REPORT 77-84 (1996) (recommending more private and public
funding of research on diet and disease, and surveying advantages and disadvantages of
exclusivity, royalties and other means of providing incentives).
242. See 21 U.S.C. § 355(4)(D) (1997); KEYSTONE REPORT, supra note 241, at 82.
243. See, e.g., 7 U.S.C. §§ 4501-4514 (1994); OLAN D. FORKER & RONALD W. WARD,
COMMODITY ADVERTISING, THE ECONOMICS AND MEASUREMENT OF GENERIC PROGRAMS
(1993).
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preventative effects where such studies are especially difficult to
perform or to finance. 2"
The problem also arose concerning OTC drugs in need of additional
studies to meet the standards of the OTC review. These products were
also generic products that were no longer patented. The need to establish
general recognition precluded any efforts to maintain exclusivity for the
research to support claims.245 Nonetheless, the very need to support the
claims by adequate research provided the drug companies making the
OTC products the incentive to do the research during the time the
products remained on the market.
Moreover, the OTC uses of herbal products for which manufacturers
may be seeking recognition do not necessitate long-term or elaborate
studies. Proof that a sleep aid or a laxative works does not require a
multi-year study. The lack of research incentives for herbal remedies
should stimulate study of the means to provide such incentives, but
should not lead to a lower standard for determining that a product is
effective.246
B. The Freedom of Choice Rationale
1. The Supporting Theory
If there is a justification for an alternative system with a lower
standard of efficacy, it would seem to be to allow the consumer the
freedom to use a product even when the efficacy of the product has not
been adequately proven so long as use is on an informed basis, the
product is safe, and there are safeguards against indirect harm. The
product would not be presented as being effective like other drugs, but
as lacking the testing needed to have the usual assurance of efficacy. If
such an alternative system were ever to be established, the product
would need to bear a disclaimer to alert the user of this difference. For
example, the product should bear prominently the following type of
disclaimer: "This product has neither been generally recognized as
effective by experts, nor approved by the FDA, based on adequate and
'
well-controlled studies."247
In addition, the labeling should indicate that

244. See COMMISSION REPORT, supra note 16, at 69, 70.
245. See Hutr & MERRILL, supra note 29, at 608.
246. The difficulties in doing long-term studies has led to the adoption of a standard based
on significant scientific agreement for health claims on foods under the NLEA. See discussion
supra pts. II.E. & III.A. These tests, which can involve epidemiological studies to determine
lifetime effects, present difficulties that are different than the type of testing normally involved
in establishing the efficacy of OTC drugs.
247. See COMMISSION REPORT, supra note 16, at 52-54 (example of disclaimer
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the product is not intended for continued use without consulting a
physician, and, possibly, that the user should exercise judgment when
using a product that does not have the support ordinarily needed for
drugs.
The case for this type of approach has been suggested by a former
head of the FDA's Center for Drug Evaluation in the context of
discussion regarding products like Laetrile, a purported cancer cure
made from apricot pits:24
It may not be wise.., to continue the pretense that
substances such as laetrile must either be accepted as
therapeutic drugs or be suppressed. The drug regulatory law
deals with science, and to risk its essential features in the
political arena over relatively innocuous products is to court
a serious long-term setback to the rational control of
powerful chemicals in our society. We may well be better
off to tolerate a few follies in our marketplace. But again
the choice is between competing good values-do we want
scientific rationality or personal freedom? And if we want
the latter, are we willing to pay the price of a few frauds
here and there?249
In my view, a serious study is necessary to understand the implications of a freedom-of-choice rationale and the regulatory structure of an
alternative system that rests on that rationale. Based on that type of
study, a more informed judgment might be made about the policy tradeoffs, and whether such a system is better than the indirect means of
providing freedom of choice through the availability of dietary
supplements. The discussion below examines some of the factors that
would need to be considered in such a study.

recommended by individual Commission member).
248. The FDA's statutory authority to apply the new drug requirements to Laetrile, even
when use was sought by a dying patient, was upheld by the Supreme Court in Rutherford v.
Hayes, 439 U.S. 1127 (1979). The constitutional right of privacy does not require the availability
of a particular therapy to a dying patient. See Rutherford v. Hayes, 616 F2d 455, 457 (10th Cir.

1980).
249. J. Richard Crout, The Nature of Regulatory Choices, 33 FOOD DRUG COSM. L.J. 413,
422 (1978).
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2. Implications and Points for Study Under a Freedom of
Choice Rationale for Supplemental Aids
a. Consumer Protection
The disclaimer suggested above would provide consumers their
principal protection against traditional products that simply do not work,
or that do not have the support the consumer expects. The consumer
would be informed that the support for the product does not meet the
"gold standard" of proof of efficacy. They can then make an informed
choice to use a product with only a "bronze" or "copper" level of
support.
Study would be needed about how to adequately convey the
disclaimer in media advertising. A major impact of allowing any
alternative category would be the opportunity for these products to make
therapeutic claims on TV and radio. It might be necessary to require an
oral disclaimer, rather than merely the print statement typically given for
more routine information.
Use of a government-funded independent panel to approve claims for
traditional products, as is done in Germany, is problematic as a
consumer safeguard. Having pre-market approval to assess the strength
and weakness of traditional uses is in conflict with allowing the
consumer to make the choice. Furthermore, it would put the FDA in the
role of evaluating the strength of traditional use as support for permitting therapeutic use, and thereby take the agency away from the area of
its scientific expertise.
To give consumers some protection from fraud, the manufacturers
should have to substantiate the truth of any specific claims they make,
and should be precluded from making misleading claims about the
specific support for products. Thus, if a manufacturer were to claim that
palm leaves have been traditionally used in Iceland to cure colds, the
FDA would be able to examine the affirmative support the manufacturer
purports to have, and take enforcement action based on deception about
the specific claim. If the manufacturer claims to have support from
specific studies, the manufacturer should disclose other information
needed to prevent consumers from being materially misled, such as
information about studies that produce different results, or that scientists
generally do not accept the result.' If it is not possible to make a

250. See 21 U.S.C. § 321(n) (1994) (calling for consideration of misleading omissions in
determining whether a claim is misleading); Research Labs., Inc. v. United States, 167 E2d 410,
417-20 (9th Cir. 1948).
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specific claim about the support for the product without misleading
consumers, the labeling should not refer to the specific support."'
To enable the FDA to perform this minimal enforcement role, the
FDA would need adequate resources. The equivalent of "user fees"
should be required of those who market herbal remedies to assure that
the statutory safeguards are observed.252 The FDA also would need
clear authority to obtain access to the substantiation file relied on by the
manufacturer.
b. Safety
The products would also have to be safe, with safety determined
based on the adverse effects posed by the product, without any weighing
of the risks against the benefits. That type of weighing process used in
approving drugs 3 is inappropriate when the benefits have not been
adequately proven. Such a test for safety also better protects consumers
who will be experimenting with the products to determine if they work
for them. The manufacturer would have to substantiate the safety of the
product. If the product is not generally recognized as safe, the disclaimer
on the label should inform consumers of the lack of recognition.
c. Scope of Remedies Covered
A special category for traditional herbal remedies, with a lower
standard of efficacy for making therapeutic claims, will present a classic
example of the slippery slope. Criteria will have to be developed to
determine what makes something a traditional use. A decision will have
to be made whether the category is limited to herbs and plants, or
whether it also includes animal parts, like deer antlers, bear claws, and
other parts of the anatomy that have a history of use in some traditional
medicines. Vitamins, minerals, amino acids, other dietary supplements,
and OTC drugs may seek similar leniency, especially if the products are
safe and purport to have some studies or use by doctors to provide some
equivalent indication of efficacy. Special treatment for herbal remedies
would have to be justified on the grounds that traditional use is an
especially reliable indicator of effectiveness that distinguishes these

251. See Peeler & Cohn, supra note 145 (discussing difficulty in developing qualified
claims about differences of opinion in advertising claims).
252. See 21 U.S.C. § 379h (as amended by § 103, 111 Stat. at 2299 (creating authority to
assess user fees for prescription drugs).
253. See HearingsBefore a Subcomm. of the House Comm. on Govt. Op., 88th Cong., 2d
Sess. (1954) (testimony of FDA Commissioner George Larrick), reprintedin HUTrr & MERRILL,
supra note 29, at 522.
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products from others. That distinction will test one's belief in the
adequacy of traditional experience to demonstrate efficacy.
Under the freedom-of-choice model, there would be no reason to
limit the claims solely to traditional or herbal remedies. Other products
would be eligible so long as they bore the disclaimer, were safe, were
substantiated as to any specific claims, and were limited to OTC claims
when sold directly to consumers.
An appropriate name for this broader category would be "Supplemental Products." That designation helps to indicate that consumers
should consider use in relationship to the availability of tested drugs,
and should consult their physician about continued use and when the
condition worsens.
d. Limitation to OTC Uses and Incurable
Life-Threatening Conditions
If any alternative category were to be legislatively created for safe
products, such products ordinarily should be suitable for self-medication.
The OTC limitation protects the consumer from indirect harm. Drugs
may need to be issued by prescription because of their toxicity or
because of the need for a medical diagnosis to be sure that the user is
not suffering from a more serious condition with which the symptoms
may be confused.
A limitation of the alternative category solely to OTC claims raises
a tension with the freedom-of-choice rationale, however. Laetrile to treat
cancer has a claimed use that is not an OTC use. Those who are
suffering from cancer or other life-threatening diseases for which there
is no known treatment will be the ones who are most interested in using
alternative products. While sufferers from AIDS, macular degeneration,
or other incurable conditions may be the most eager to try something
that provides some hope, that hope is likely to be illusory." Still,
allowing patients to pursue their hopes for a cure, even if it is not a
promising hope, is the choice they want. Those suffering from serious
medical conditions for which there is no effective treatment present
more sympathetic cases, but also more difficult cases for allowing
freedom-of-choice, than those who are using alternatives for minor
conditions."

254. For discussion expressing concern over the availability of drugs without testing and
the inadequacy of disclaimers, see George J. Annas, Faith (Healing), Hope and Charity at the
FDA: The Politics of AIDS Drug Trials, 34 VILL. L. REV. 771 (1989); George J. Annas,
Questingfor Grails: Duplicity,Betrayal and Self-Deception in Postmodem Medical Research,
12 J. CONTEMP. HEALTH L. & POL'Y 297 (1996).
255. See John P. Dillman, Note, Prescription Drug Approval and Terminal Diseases:
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One way to deal with this tension would be to allow the supplemental remedies offered for uses not suitable for self-medication to be
available only by prescription. The products would be subject to the
same limits discussed above, but the effectiveness claims for the
products would appear only in the professional labeling provided to the
physician. The same disclaimers would be made available both to the
physician and to the patient. The need to consult a physician would
provide assurance that the patient had been advised about the conventional therapies and the value of the claimed remedy before the patient
choses to use the alternative.
The manufacturer who promotes drugs for incurable serious medical
conditions should provide more information to doctors to enable the
physician to advise the user about the alternative. The manufacturer
should be required to have the drug evaluated by an independent
qualified expert who assesses the adequacy of any testing the manufacturer claims to have. The expert also would identify the additional
testing that would be needed to determine efficacy under the usual
standards. That information would be available as part of the drug
labeling provided to lhe physician, and would be periodically updated.
Under this approach, the FDA would identify a list of expert reviewers
whom the manufacturer could use to make the evaluation. Further
consideration would be needed regarding whether post-approval studies
should be required for these products.
Some investigation would also be necessary concerning the ethical
issues faced by a physician in prescribing a drug when the physician
knows that the product has not been adequately tested. That investigation may need to consider in more depth the type of information the
physician should disclose to the patient in these circumstances.
The FDA has recognized that some drugs are appropriately sold
over-the-counter even though they are to be used only after consultation
with a physician. 6 That model might possibly be appropriate for some
supplemental products already sold directly to consumers to treat
conditions that need professional diagnosis and treatment. In such a
case, the product still would bear the disclaimer described above and
would provide instructions and warnings for the ordinary use of the
product. The label would not describe the specific therapeutic use on the

Desperate Times Require Desperate Measures,44 VAND. L. REV. 925 (1991).
256. See 44 Fed. Reg. 16,126 (1979) (addressing treatment of vitamin deficiencies); Hurr
& MERRILL, supra note 29, at 409. While the FDA permits the therapeutic use to be indicated
on the label in these cases, the specific use would not be indicated on the label of the remedies
covered by this proposal. Only the identity of the supplement and the need for professional
consultation would be on the label.
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label, but would instead only identify the active ingredient, along with
the statement that product is to be used only after consultation with a
physician on its usefulness for other purposes.
If an alternative system were adopted, it would presumably not lead
to reimbursement of the supplements by insurance plans. Plans that
cover drugs typically do not provide reimbursement for over-the-counter
or experimental drugs. If a consumer wishes to use a remedy of
unproven efficacy, but has to pay the cost, the consumer may consider
the decision with added seriousness.
e. Non-Applicability to Potent Drugs
The alternative system to be studied should be limited to safe drugs
even when use is limited to prescription sale. When a drug poses direct
risk of physical harm, the efficacy of the drug should be established to
justify the risk, or the drug should be part of a genuine study to
determine the efficacy of the product that is part of the new drug
approval process.'
Any alternative system should not replace the need for approval of
an NDA for potent drugs. The FDA has developed procedures to speed
up the approval of therapies that offer promise in treating life-threatening and serious health-impairing conditions." Congress also has
recently adopted further measures to expedite fast track approval of
drugs for life-threatening conditions, and to permit investigational uses
in emergencies.259
f. Implications for DSHEA
If an alternative system were to be adopted under any rationale, some
consideration would need to be given to its potential implications for
257. For analysis of the FDA's procedures and possible changes, see, for example, Steven
R. Salbu, Regulation of Drug Treatmentsfor HIV andAIDS: A ContractarianModel of Access,
11 YALE J. ON REG. 401 (1994); Lois K. Perrin, Note, The Catch-22for Persons with AIDS: To
Have or Not to Have Easy Access to Experimental Therapies and Early Approval for New
Drugs, 69 S. CAL. L. REV. 105 (1995); Ronald Podraza, The FDA's Response to AIDS:
Paradigm Shift in New Drug Policy?, 48 FOOD & DRUG L.J. 351 (1993); Marsha N. Cohen,
Getting New Drugs to People with AIDS: A Public Policy Response to Lansdale, 18 HASTINGS
CONST. L.Q. 471 (1991).
258. See Nancy K. Plant, Adequate and Well-Controlled Clinical Trials: Reopening the
Black Box, I WIDENER L. SYMPOSIUM J. 267, 293-96 (1996) (surveying measures to speed up
approval of drugs used to treat AIDS and some other drugs, and noting debate among some
activists about the advantages of the conventional testing process).
259. See 21 U.S.C. §§ 351-506 (as added by § 112, 111 StaL at 2309-10) (addressing
accelerated approval of drugs for life-threatening conditions); 21 U.S.C. § 561 (as added by §
402, 111 Stat. at 2365-67 (providing for expanded access to unapproved therapies).
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DSHEA. Should the scope of "statements of nutritional support" be
revisited because such statements might be used to indirectly suggest
therapeutic uses? Should such indirect claims be permitted when
Congress has legislatively provided for the means for making therapeutic
claims?
Would the exemption provisions from labeling of publications about
dietary supplements be appropriate if an alternative system were
adopted? The publications now can be used to suggest therapeutic uses
that do not have the amount of testing or meet the other conditions
necessary to be a permissible claim on the label. If therapeutic claims
were to be allowed on the label without full testing under the alternative
system, but subject to some statutory safeguards and strong disclaimers,
would the publications exemption be a means to circumvent these
safeguards?
Are there any implications for products sold as dietary supplements
that are widely used by consumers for therapeutic purposes, even though
the claims by the manufacturer on the products relate solely to use as
dietary supplements?
While these questions need study, the industry is likely to oppose
any legislative change establishing an alternative system that might be
accompanied by a change in the provisions of DSHEA.2
VI. CONCLUSION

The primary focus for the present should be the appropriate
interpretation and implementation of DSHEA. Better guidance is needed
on ways to distinguish statements of nutritional support from disease
claims. Meaningful identification of what makes a claim a dietary one
can help make that distinction. Considering the analogy to food uses,
linking the claim to use as a food substitute, distinguishing uses
unrelated to the diet, and precluding prescription uses that need
professional supervision, are important steps in identifying dietary
claims.
The publications exemption is particularly troublesome because it
enables product promoters to use materials relating to disease claims in
connection with sale without any prior FDA review. The Commission

260. Combined Presentation, American Herbal Products Ass'n, National Nutritional Foods
Ass'n, and Utah Natural Products Alliance, Combined Presentation to the Commission on
Dietary Supplement Labels, Eighth Meeting (Baltimore, Md. 1997) (stating that there should be
no separate regulatory category under DSHEA for herbal remedies and related products); Council
for Responsible Nutrition, Statement of John Cordaro to the Commission on Dietary Supplement
Labels (Mar. 4, 1997) (opposing "the creation of a new statutory or regulatory category for
herbal products that would require an amendment to DSHEA").
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Report has identified some factors that are helpful in ensuring that the
scientific information is balanced and non-misleading. The publications
exemption also should be limited to independent writings about the
scientific information not written or developed by the manufacturer or
seller of the supplement. The applicability of the exempted material to
prescription uses that need medical supervision needs further review.
Manufacturers also need to have an enforceable obligation to
substantiate the safety of all supplements. The FDA has to be able to
enforce the substantiation requirement effectively and efficiently if that
obligation is to have any content. Accordingly, the FDA needs to be
able to obtain access to the substantiation records of manufacturers both
with respect to safety and structure or function claims.
An enforceable substantiation obligation provides an intermediate
model for regulation that does not involve pre-market review, but that
also does not rely solely on a reactive approach focused on court
enforcement. DSHEA can provide a test of this type of intermediate
regulatory model as a way of providing consumer protection for
products that are labeled for use as a dietary supplement with dietary
claims, but not with disease claims.
If supplements are sold for therapeutic purposes, a greater level of
regulatory scrutiny is appropriate. To ensure that the disease claims are
valid, controlled testing is needed, along with review by the agency to
make sure that the testing requirements have in fact been met. The
standards and regulatory review should be the same required for other
products that make disease labeling claims.
If botanical products or other supplements are to be legislatively
exempted from these requirements, policy makers will have to consider
the serious issues involved in creating an alternative system of regulation for therapeutic claims. The approach that seems to most warrant
study, in my view, would allow therapeutic claims for safe supplemental
products of various types simply on the basis of allowing the consumer
to exercise their freedom to choose, on an informed basis, to use a drug
that has not been adequately proven to be effective. The consumer
would need clear disclaimers on the label and in advertisements that the
product neither has adequate testing nor the most reliable support. That
approach has some theoretical appeal, but there are difficulties in
providing understandable disclaimers to consumers. Clear disclaimers
about the lack of adequate studies may discourage many manufacturers
from being willing to make claims.
Study also would be needed about the extent to which the products
should be limited to over-the-counter uses. Consideration might be given
to allowing safe products to be used for conditions requiring medical
supervision, but only with a prescription or after consultation with a
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physician and without making direct claims to the user. In such cases,
the manufacturer would also need to provide an independent assessment
of the product for use by the physician.
The manufacturer also should be precluded from making any
misleading claims about the specific basis relied upon for the claim. The
manufacturer would have to substantiate the specific claims. The FDA
would be given the inspection authority and resources from fees paid by
manufacturers to enforce the limitations.
Even with the safeguards, some may view this freedom of choice
alternative as unacceptable. Disclaimers, no matter how candid, may be
insufficient to protect consumers from the confusing claims that newfangled snake oil salesmen might make. Moreover, there is valid
concern that any alternative represents a retreat from the present drug
efficacy testing requirements, and that further erosion would occur even
for potent drugs.
Others may favor a different alternative system. They may favor a
system derived from international models that would allow sale based
on traditional use, without requiring controlled studies. Approval of the
claim by an expert panel may be required, but not the usual FDA
review. The products might bear a label statement that indicates the
support the product has (such as that it has been traditionally used in
certain countries), but not a disclaimer that indicates the lack of testing
and expert recognition or FDA review presently needed for drugs in the
United States. The latter type of disclaimer may discourage sales, and
some may believe it unnecessary. On the other hand, without such a
clear disclaimer, this type of alternative approach does not seem to be
one that adequately protects consumers.
There are drawbacks to the present system and the indirect way that
the availability of dietary supplements provides freedom of choice,
under DSHEA, to consumers who choose to use supplements for
therapeutic purposes, on their own, or based on exempted publications.
The difficulty of identifying an alternative that is better, that is
acceptable to the industry, and that adequately protects the public, is
likely to leave DSHEA, with its ambiguities and limitations, in place.
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